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High performance affinity chromatography (HPAC) is a technique that uses a biologicallyrelated agent such as a transport protein or an antibody as the stationary phase in an HPLC system.
In recent years, HPAC has been shown to be a valuable bioanalytical tool for studying soluteprotein interactions. Human serum albumin (HSA), the most abundant protein in blood (with
concentrations of 35 to 50 mg/mL in serum), has been shown to interact with many drugs, affecting
their transport, excretion and metabolism. A physical method for immobilizing proteins in HPAC
supports has been optimized in this dissertation by using HSA as a model protein.
This method involved the encapsulation of this protein inside the pores or near the surface
of hydrazide-activated silica by using mildly oxidized glycogen as a capping agent for the
hydrazide groups. Previous work has shown that this approach is able to retain the activity of the
entrapped protein and to produce binding that is comparable to what is seen for the protein in its
soluble form.

The entrapment process was optimized in a slurry based-format by altering the purification
method for the oxidized glycogen, as well as increasing the concentration of protein and decreasing
the total reaction volume that were used in this format. Through these changes, it was possible to
obtain HPAC stationary phases with a nine-fold increase in their retention factor for warfarin. An

on-column entrapment approach was also examined, in which HSA and oxidized glycogen were
reacted with hydrazide-activated silica in a flow-based format. This second approach provided
retention factors for warfarin that were up to three-fold higher than those obtained by the slurry
method. The ability of the on-column method to produce higher capacity stationary phases was
then exploited for making chromatographic supports capable of separating sugars by using
immobilized lectins. This on-column approach was also used for studying the effects of glycation
of HSA on its binding properties with various sulfonylurea drugs that are used to treat diabetes. It
was found that normal HSA and HSA with various levels of glycation, as immobilized by
entrapment, did show changes in their drug binding parameters that depended on the level of
glycation.

Finally, organic monoliths containing silver nanoparticles (AgNPs) were placed on glass
slides and within microchannels and used for detecting a near infrared fluorescent dye. Up to tenfold enhancement in the fluorescence signal of the dye was obtained for monoliths containing
AgNPs when compared to control monoliths. This higher sensitivity can be exploited in making
stationary phases or detection elements in microfluidic devices that can be utilized in the analysis
of small samples and in applications such as flow-based biointeraction studies.
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CHAPTER 1.

1.1.

INTRODUCTION

HIGH PERFORMANCE AFFINITY CHROMATOGRAPHY
High performance affinity chromatography (HPAC) is an analytical technique that

combines the instrumentation, speed and efficiency of high performance liquid
chromatography (HPLC) with the highly selective nature of affinity chromatography (AC)
[1,2]. This liquid chromatographic technique uses the reversible interactions that are
common in many biological systems, such as enzyme-substrate and antibody-antigen
interactions. One of the components of such a system is coupled to a chromatographic
matrix and placed into a column where it makes up the stationary phase (or “affinity
ligand”). The other component is dissolved in the mobile phase and used as an applied
target or analyte. The interactions between the affinity ligand and the analyte are usually
quite strong and specific, allowing for the use of affinity chromatography in the purification
and analysis of target compounds in complex samples [1-5].
The affinity ligand can be either a biological agent, such as a protein, or a synthetic
molecule that mimics some of the binding properties of a natural compound. Examples of
proteins that have been used as affinity ligands are human serum albumin (HSA), α1-acid
glycoprotein (AGP), and antibodies (or immunoglobulins). Lectins from plants are affinity
ligands that also belong to this category. Examples of synthetic molecules that have been
used as affinity ligands are boronic acids, metal ion chelates and biomimetic dyes [5-7].
When the affinity ligand (e.g., a protein) is immobilized onto a support that is
suitable for use in high performance liquid chromatography (e.g., porous silica beads), the
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resulting technique is known as HPAC. This method can be used in separations to
conveniently isolate, measure, or study specific target-ligand interactions even when the
applied targets are present in complex biological samples. Automation in HPAC can allow
a drastic reduction in analysis times and the sample sizes that are required for the study of
biological interactions when compared with other well-established techniques such as
ultrafiltration and equilibrium dialysis. Another advantage of HPAC is its ability to reuse
the same biological agent for many studies [1,2].

1.2.

COVALENT IMMOBILIZATION AND IMMOBILIZATION

EFFECTS
Covalent attachment is frequently used for immobilizing a ligand to an HPAC
support. Functional groups such as amine, sulfhydryl, carbonyl or hydroxyl groups are
commonly used for this process. Among these groups, amines have been widely used in
the immobilization of proteins to silica supports for use in HPAC [4,8-13]. The Schiff base
method is one example of such a technique [14]. The stability of the linkage between
amine groups on a protein and aldehyde groups on a modified support has made this
method attractive for work with proteins and antibodies [14]. However, covalent coupling
methods can often have issues like multisite attachment, improper ligand orientation and
immobilization near the active site of a ligand, which can lead to a decrease in or loss of
the ligand’s activity [5].
Multisite attachment refers to the coupling of an affinity ligand to a support through
more than one functional group on the same ligand. This effect can stabilize the attachment
of an affinity ligand to the support but can also deform the active site of the affinity ligand,
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affecting its binding capacity. Improper orientation occurs when the site of attachment for
an affinity ligand is at or near its active region. Steric hindrance occurs when this active
site is blocked by the support or by neighboring affinity ligands. These factors can render
the active site more difficult to reach by the target analyte. These problems (e.g., multisite
attachment or improper orientation) may be present to some extent when immobilizing
affinity ligands that are proteins and when using amine-based coupling methods, because
amine groups may be present at many locations in such binding agents [5].

1.3.

ENTRAPMENT
To overcome effects such as steric hindrance and improper attachment that can

occur during the use of covalent immobilization methods, and to obtain protein-based
stationary phases with high activities, alternative immobilization methods based on
entrapment have been explored [5,15-19].

This approach involves the physical

containment or encapsulation of an affinity ligand in a support that contains small pores or
a highly cross-linked polymer network [5]. Entrapment has been extensively used in work
with sol-gels for drug release and for applications involving low performance separations.
However, most of these materials are not suitable for use in HPAC because of their inability
to withstand high pressures and their slow mass transfer properties [15-17].
Recent work was conducted using entrapment with HPLC-grade silica and was
tested by using HSA as a model affinity ligand [20]. This method has been employed for
examining the interactions of HSA with sulfonylurea drugs by HPAC [21].

The

entrapment procedure that was used in these studies involved placing HSA into a slurry
containing hydrazide-activated porous silica and glycogen that had been mildly oxidized
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by treatment with periodic acid to form aldehyde groups on the glycogen. The aldehyde
groups on the glycogen were able to react with the hydrazide groups on the silica to form
stable covalent bonds, while the HSA remained free in solution. During this reaction, some
of the HSA became entrapped in a soluble form near the surface of the support or within
the pores of the silica particles with no apparent loss of activity. Because glycogen is a
large and highly branched carbohydrate polymer, the entrapped HSA was blocked by this
polymer from leaving the support, but it was still possible for this protein to be reached by
small molecules that could pass into and out of the pores of the support or reach its surface
[20,21]. Besides providing good activity and avoiding many of the undesirable effects of
covalent immobilization, this entrapment approach could be extended to other proteins and
relatively large affinity ligands [20].

1.4.

QUANTITATIVE AFFINITY CHROMATOGRAPHY
Although affinity chromatography was initially used for the isolation of biological

compounds, over the past few decades a great deal of work has been done using this method
for chemical analysis in areas such as biochemistry, pharmaceutical science, clinical
chemistry, and environmental testing. In addition, the role of affinity chromatography in
these fields has involved an increasing emphasis on the use of this method as a tool for
studying the strength and rates of biological interactions, as well as in characterizing the
number and types of binding sites that are involved in these interactions [2,4,22-24].
Several parts of this dissertation are concerned with the use of affinity
chromatography and HPAC for the study and characterization of biological interactions.
This type of application is also known as quantitative affinity chromatography or analytical
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affinity chromatography. One advantage of using HPAC for this type of work is the ability
to often reuse the same preparation of an immobilized affinity ligand for multiple
experiments. This feature reduces the total amount of affinity ligand that is needed to
conduct a series of experiments and reduces the cost per analysis. In addition, using the
same affinity ligand preparation for many experiments helps to improve the reproducibility
and precision by minimizing batch-to-batch and run-to-run variations. Finally, the ability
of HPAC to make use of HPLC instrumentation allows for the automation of this method
and reduces contamination of the columns between experiments by continuously washing
the stationary phase with the mobile phase [25].
One experimental format that is used in HPAC for studying biological interactions
is zonal elution (or “ZE”). This method involves making small injections of a probe
compound or the analyte into a column that contains the immobilized affinity ligand. The
outcome of this experiment is a peak for the probe or analyte that can be monitored by online detection. The most common parameter that is obtained from this chromatogram is
the retention time of the injected compound, which is then used to help characterize the
binding of this compound to the affinity ligand in the presence of a given mobile phase
(e.g., a buffer that mimics physiological conditions or the natural environment of the
affinity ligand) [1,25].
The binding between the applied analyte (A) and an affinity ligand (L) immobilized
in a chromatographic column can be described by the following equations for a system
with a 1:1 interaction,
𝐴+𝐿↔𝐴−𝐿

(1.1)

𝑘

[𝐴−𝐿]∗

𝐾𝑎 = 𝑘𝑎 = [𝐴][𝐿]∗
𝑑

(1.2)

6
where AL is the analyte-ligand complex, Ka is the association equilibrium constant
for the formation of this complex, ka and kd are the association and dissociation rate
constants for this complex, and [L]* or [A−L]* represent the surface concentrations of the
affinity ligand and analyte-ligand complex at equilibrium [8,9]. These equations indicate
that the retention of an analyte or target compound in an affinity column is determined by
several parameters, such as the strength of the ligand-target interaction (e.g., Ka) and the
amount of the immobilized affinity ligand that is present (e.g., [L]*).
An analyte’s retention in an affinity column can be described experimentally by its
retention factor k, which is calculated as follows,
𝑘=

(𝑡𝑟 −𝑡𝑚 )
𝑡𝑚

(1.3)

where tr is the retention time of the analyte, and tm is the column void time. The
value of the retention factor is related to the association equilibrium constant and the
amount of active affinity ligand in the column, as is indicated for a 1:1 reaction in Equation
(1.4),
𝑚

𝑘 = 𝐾𝑎 𝑉 𝐿
𝑀

(1.4)

where mL is the moles of active affinity ligand, and VM is the column void volume.
The ratio mL /VM in this equation is the effective concentration of the affinity ligand in the
column [8,9]. If the mobile phase during a zonal elution experiment contains other agents
(e.g., competing solutes), it is further possible to use this type of study to obtain information
on how these agents may affect the analyte-ligand interaction [8,9,25].
Another important format that can be used for studying a biological interaction by
HPAC is frontal analysis (or “FA”). In this approach, a solution containing a known
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concentration of a target analyte is continuously applied to an affinity column at a constant
flow rate. As the target binds to the immobilized affinity ligand, the column becomes
saturated and the amount of target that is eluting from the column gradually increases. This
forms a breakthrough curve, which is essentially a titration of the active ligand in the
column. If relatively fast association and dissociation kinetics are present on the time scale
of this experiment, the mean position of the breakthrough curve can be used to determine
the amount of active affinity ligand that is in the column and the association equilibrium
constant of the affinity ligand for the target [5,25].
When frontal analysis is used to study a biological interaction, the moles of the
target that are required to reach the mean point of the breakthrough curve are often
measured at several concentrations of the applied target, and the resulting data are fit to
various models to determine if this interaction involves one or more binding sites. The
model that best describes the data is then used to determine the equilibrium constant(s) for
the target-ligand interactions and the amount of each type of binding site in the column.
For example, in the case of a target analyte (A) that has a single type of binding site on an
affinity ligand (L), the frontal analysis results should provide a good fit to the following
equation,
1
𝑚𝐿𝑎𝑝𝑝

=𝐾

1

𝑎 𝑚𝐿 [𝐴]

1

+𝑚

𝐿

(1.5)

where mLapp is the apparent moles of the analyte that are required to reach the mean
breakthrough point for the column at a given molar concentration for the applied analyte,
[A]. The parameters Ka and mL in Equation (1.5) are the same as described earlier and can
be determined from the slope and intercept of a best-fit line to the data for a system with a
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single type of binding site. The goodness of the fit for the data to this equation can be
assessed by using such tools as the correlation coefficient and the sum of the squares of the
residuals. These and other tools can also be used to compare the fit of the data to other
possible models, such as one involving two different types of binding sites [10,13,25].
The binding capacity of an affinity column can be determined from the value of mL
that is obtained by frontal analysis [1,25,26]. When determining the binding capacity in
this way, it is important to use a relatively slow flow rate that ensures that all of the applied
analyte has sufficient time to interact with the immobilized affinity ligand [5]. The specific
activity of the immobilized ligand can be found by dividing the measured binding capacity
by the total amount of immobilized affinity ligand that is present. For instance, if the
affinity ligand is a protein, the total amount of the binding agent that is present can be
measured by an independent method such as a bicinchoninic acid (BCA) protein assay
[5,18].

1.5.

OVERALL GOALS AND SUMMARY OF WORK
It has been demonstrated recently that the entrapment of affinity ligands on

hydrazide-activated silica, by capping this support with oxidized glycogen, can be a
valuable approach for immobilizing proteins such as HSA for HPAC [20,21]. However,
this method still needs further optimization for its use with alternative affinity ligands and
in new applications. To expand the use of this technique for preparing other HPAC
stationary phases, it is necessary to conduct studies to answer the following questions.
First, “What methods can be used to increase the amount of the entrapped affinity ligand?”
Second, “What are some novel applications of affinity columns that have been prepared by
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entrapment, such as with regards to the study of biological interactions?” Third, “What are
some alternative ways of carrying out the entrapment process?”
There are several benefits to seeking the answers to these questions. One possible
outcome from this type of research would be the ability to prepare affinity microcolumns
that are suitable for the analysis of extremely small samples or that could achieve low limits
of detection. The use of entrapment to prepare small affinity columns with high binding
capacities would also be useful in situations where a limited amount of ligand is available,
such as in the immobilization of proteins from individual samples of human serum. The
creation of new approaches for entrapment, such as the use of on-line systems for column
preparation, would be useful in automating these methods and would also be of interest in
applications such as personalized medicine for studies of protein-drug interactions and the
measurement or characterization of biomarkers in samples that are taken from individuals
with diseases such as diabetes or cancer.
Chapter 2 of this dissertation will look at ways for increasing the amount of a
protein that can be immobilized through entrapment. The optimization of a flow-based
entrapment procedure will be described in Chapter 3. A fast method for studying drugprotein binding, as based on entrapped protein columns, will be presented in Chapter 4.
Finally, a platform that can be used for on-column detection in microscale chromatography
or post-column sensing in microfluidic devices, and using fluorescent dyes and monolithic
supports, is examined in Chapter 5.
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CHAPTER 2.
APPROACHES FOR INCREASING PROTEIN CONTENT
DURING IMMOBILIZATION THROUGH ENTRAPMENT

2.1.

INTRODUCTION
The interaction of small solutes with proteins in serum is important for many drugs

and biological agents. Serum proteins such as human serum albumin (HSA) and 1-acid
glycoprotein (AGP) are known to bind to many small endogenous compounds in the body,
as well as pharmaceutical agents. Drug-protein interactions in serum are often significant,
with approximately 43% of the 1500 most common drugs having at least 90% binding to
proteins in serum. These interactions can affect the free concentration of a drug in blood
and can play an important role in determining the distribution, activity, excretion, and
metabolism of such an agent in the body [1-3].
The study of drug-protein interactions has been carried out in the past by using
techniques such as equilibrium dialysis, ultrafiltration, and other solution-based reference
methods (e.g., various spectroscopic methods) [4,5].

High performance affinity

chromatography (HPAC) is a type of affinity chromatography that utilizes solid supports
consisting of small, rigid particles that can withstand the high pressures that are typical of
HPLC. These supports can provide the enhanced mass transfer properties that are needed
in HPLC for chromatographic separations and are better suited for analytical applications
than less rigid and larger diameter supports [7]. Supports that can be used in HPAC include
silica, azalactone beads, hydroxylated polystyrene media, and some types of monolithic
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columns [5,7-9]. The study of drug-protein interactions by HPAC with proteins such as
HSA and AGP has provided binding parameters that show good agreement with values
obtained by using soluble HSA or AGP [5].
One advantage of HPAC is that the same protein or binding agent preparation can
often be used for multiple experiments. Thus, only a small amount of a protein is often
required in HPAC to conduct a large number of studies. This feature is useful when a
limited amount of the binding agent is available and helps to provide good precision by
minimizing run-to-run variations in this binding agent. The speed and precision of HPAC,
as well as its ability to be automated, also make this method attractive for analytical
applications and drug-protein binding studies [8,10-12].

2.1.1. Examples of binding agents for HPAC
HSA is commonly used as an immobilized affinity ligand in HPAC to study drugprotein binding. HSA was used in this study as a model binding agent for identifying ways
of improving immobilization methods (i.e., entrapment, in this case) and for achieving a
higher protein content in columns that are to be used in HPAC. HSA is the most abundant
protein in serum and binds to numerous drugs and endogenous compounds. HSA makes
up about 60% of the total protein content in blood and has a typical concentration that
ranges from 35 to 50 g/L. This protein has a molar mass of 66,438 g/mol and consists of
a single polypeptide chain of 585 amino acids, which form a structure that is stabilized by
17 disulfide bonds. The binding of drugs to serum proteins like HSA often improves their
solubility and is an important source of interactions that may occur between some drugs
and endogenous agents such as fatty acids. These agents may compete directly or indirectly
for the same binding sites on serum proteins. This fact makes the binding by HSA and
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other serum proteins with drugs a subject of great interest to the pharmaceutical industry
[1-3]. Figure 2.1 shows the structure of HSA and the location of its two major binding
sites for drugs: Sudlow sites I and II. Sudlow site I (also known as the warfarinazapropazone site) tends to bind bulky heterocyclic compounds, while Sudlow site II (also
known as the indole-benzodiazepine site) often binds to aromatic carboxylic acids
[8,13,14].
The lectin concanavalin A (Con A) was a second binding agent that was considered
in this study. Lectins are non-immune system proteins that are often isolated from plants
and that can agglutinate cells and/or precipitate complex carbohydrates. Lectins have the
ability to bind to specific sugar moieties and have been used extensively as affinity ligands
for fractionating and isolating glycoproteins and glycopeptides. For example, Con A can
bind to mannosyl and glucosyl residues, while the lectin wheat germ agglutinin (WGA)
recognizes N-acetyl-glucosamine (GlcNAc) and sialic acid (NeuNAc) residues [15-19].
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Figure 2.1

Structure of HSA, including its two major binding sites for drugs (i.e., Sudlow
sites I and II). This structure includes a molecule of the drug R-warfarin (shown
in blue) that is bound to Sudlow site I. The image is based on PDB entry 2bxd
and was generated using Uniprot file ID: P02758 [6].

18

Sudlow site II

Sudlow site I
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Figure 2.2

The tetrameric structure of Con A, which was co-crystallized with the
glycopeptide Man-WYD. The four monomer chains are represented by
different colors. Each identical monomeric unit also includes Ca 2+ (green),
Mn2+ (purple) and the glycopeptide moiety. This image is based on PDB
entry 4czs [24].
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Con A is obtained from the jack bean and is the first lectin whose structure was
determined. It contains 237 amino acid residues and has a molar mass of 25.5 kDa. The
monomers of Con A can aggregate to form dimers and tetramers. Each monomer has one
binding site for a saccharide, one transition metal (usually Mn 2+) and one Ca2+ ion [20,21].
This binding site can interact with mannosyl and glucosyl residues of polysaccharides and
glycoproteins (i.e., groups containing C3, C4 and C6 hydroxyl groups) and can be used to
capture N-glycosylated peptides/proteins with broad specificity [22]. Figure 2.2 shows the
structure of the tetrameric form of Con A [23,24].

2.1.2. Preparation of stationary phases for HPAC by entrapment
The use of binding agents such as HSA or Con A in HPAC starts by immobilizing
such a protein on a suitable support. Porous silica with a particle size of 7 µm and a pore
size of 300 nm was selected for use in this work as the support material, due to its good
mechanical stability and mass transfer properties. This same material has also been used in
many previous studies with HPAC based on the same or similar proteins to those that were
used in this current study [3,25-27]. The particle size and pore size selected for this support
in this study have been found in a prior report to provide the highest protein content for
similar supports that have been prepared by using protein entrapment [28].
The porous silica that was used as a starting material for this work was converted
to a hydrazide-activated form for use in protein entrapment, according to a previously
published procedure [29]. As can be seen in Figure 2.3, the first step was to treat the silica
particles with 3-glycidoxypropyltrimethoxysilane, followed by the addition of dilute
sulfuric acid to generate diol-bonded silica. This material was then dried and could be
stored as an intermediate support for several months prior to its use for protein entrapment.
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The next step was to oxidize part of the diol-bonded silica with periodic acid to create
aldehyde groups on the surface of the support. This was followed by the reaction of these
aldehyde groups with a homobifunctional hydrazide reagent to create hydrazide-activated
silica. In this study, oxalic dihydrazide was added to the aldehyde-activated silica to form
the hydrazide-activated support, and sodium borohydride was later added to reduce and
remove any aldehyde groups that were still on the support.
In the next step of the entrapment process, a slurry containing the hydrazideactivated silica in pH 5.0, 0.10 M potassium phosphate buffer was combined with the
protein that was to be entrapped (e.g., HSA or Con A) and a mildly oxidized form of
glycogen, which was used as a capping agent. During the entrapment process, aldehyde
groups on the oxidized glycogen were allowed to react with hydrazide groups on the
support. At the same time, part of the protein became trapped by the glycogen in the
support and remained in a soluble form (see Figure 2.4) [28,30].
Previous work has shown that this entrapment process can place proteins onto a
silica support while maintaining their biological activity [30]. The purpose of this current
study was to further optimize this method to increase the final protein content. A high
protein content was desired because it should result in higher resolution and binding
strengths for the resulting HPAC columns. The activity of HSA columns that were made
by this method was monitored by using warfarin and carbamazepine, whose interactions
with HSA are well-characterized [26,31-36]. The activity of columns prepared with Con
A were measured by using 4-methylumbellipheryl α-D-mannopyranoside (MUM), which
can be detected by absorbance or fluorescence; and has a relativley high affinity for Con
A [17].
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Figure 2.3

Scheme for the preparation of hydrazide-activated silica from porous silica
particles. Adapted with permission from Ref. [29].
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Figure 2.4

Scheme for protein entrapment by the reaction of mildly-oxidized glycogen
with hydrazide-activated silica. Adapted with permission from Ref. [28].
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2.2.

EXPERIMENTAL SECTION

2.2.1. Reagents
HSA (essentially fatty acid free, purity ≥ 96%), Con A (type V, lyophilized powder,
purity ≥ 99%), bovine serum albumin (BSA, fraction V, purity ≥ 96%), glycogen (bovine
liver, type IX, total glucose ≥ 85%, dry basis), racemic warfarin (purity ≥ 98%), MUM
(purity ≥ 96%), 4-methylumbellipheryl α-D-galactopyranoside (MUGA, purity ≥ 98%),
periodic acid reagent (H5IO6, purity 99%), Lucifer yellow CH (LyCH, purity ≥ 85%),
fluorescein isothiocyanate (FITC, isomer I, purity 90%) and FITC-BSA conjugate (purity
90%) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Nucleosil Si-300 silica
(7 m particle diameter, 300 Å pore size, 100 m 2/g surface area) was obtained from
Macherey Nagel (Düren, Germany). A micro-bicinchoninic acid (BCA) protein assay kit
was purchased from Pierce (Rockford, IL, USA). All other chemicals were of the purest
grades available. Econo-Pac 10DG disposable desalting columns (3.3 mL void volume, 6
kDa exclusion limit; BioRad, Hercules, CA, USA) and Vivaspin 6 ultrafiltration tubes (30
kDa cutoff; Sartorius, Götingen, Germany) were used for glycogen purification. All
buffers and aqueous solutions were prepared using water from a Nanopure system
(Barnstead, Dubuque, IA, USA). Buffers were filtered using 0.20 μm GNWP nylon
membranes from Millipore (Billerica, MA, USA) and were degassed by sonication under
vacuum for at least 20 min prior to use.
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2.2.2. Apparatus
The chromatographic system consisted of a 1200 isocratic pump from Agilent
(Santa Clara, CA, USA) and a Series 200 UV-Vis detector plus a vacuum degasser from
Perkin-Elmer (Waltham, MA, USA). Samples were injected using a Rheodyne LabPro
valve (Cotati, CA, USA) that was equipped with a 5 µL or a 20 µL loop. An Isotemp 9100
circulating water bath (Fisher Scientific, Pittsburgh, PA, USA) and a water jacket from
Alltech (Deerfield, IL, USA) were used for temperature control of the columns. The
chromatographic data was collected using LabView 8 software (National Instruments,
Austin, TX, USA) and analyzed using PeakFit 4.12 (Systat Software, San Jose, CA, USA).
A Pack in a Box system (ChromTech, Apple Valley, MN, USA) was used for
packing the supports into columns. A UV-160A spectrophotometer (Shimadzu, Kyoto,
Japan) was used for the BCA protein assay.

A Cary Eclipse fluorescence

spectrophotometer (Varian, Palo Alto, CA, USA) with a microplate reader adaptor was
used for the protein assay based on fluorescence. The thermogravimetric analysis of silica
samples was performed using a TGA7 system (Perkin Elmer, Waltham, MA, USA)
equipped with nitrogen flow for inert analysis conditions and data collection software.

2.2.3. Preparation of entrapped protein supports
The columns containing entrapped proteins were prepared from Nucleosil 300-7,
HPLC-grade porous silica that had been converted into diol silica, as based on a previous
procedure [29]. The diol silica was dried and stored for future use. Batches of this silica
were converted into hydrazide-activated silica by following a procedure that has also been
described in the literature [29].
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The initial conditions used for entrapment were based on previous work [28] and
involved making a slurry containing 0.08 g of hydrazide-activated silica and 0.8 mL of 10
mg/mL HSA in pH 5.0, 0.10 M potassium phosphate buffer. This slurry was degassed in
a sonication bath for 10 min to ensure there was no trapped air within the support. Next,
0.28 mL of a 4.25 mg/ml solution of mildly oxidized glycogen in the pH 5.0, 0.10
phosphate buffer was added (i.e., an amount equivalent to 15 mg glycogen/g silica). The
glycogen had been previously oxidized with periodic acid reagent in a pH 5.0 buffer
containing 20 mM sodium acetate and 15 mM sodium chloride, as well as 17 mg of
glycogen and 135 mg of the periodic acid reagent in 4 mL of this buffer; this oxidation was
done for a period of 16 h in the dark. The volume of solution for the entrapment reaction
was then adjusted to 2 mL by adding pH 5.0, 0.10 M phosphate buffer. This slurry was
placed on a rotation mixer for 16 h at 4 °C. Finally, 50 µL of oxalic dihydrazide (at a
concentration of 1 mg/mL in pH 5.0, 0.10 M phosphate buffer) was added and allowed to
mix with this slurry for 1 h to cap any remaining aldehyde groups on the glycogen and to
decrease possible non-specific binding of other solutes to the column. Control supports
were prepared in the same manner, but with only buffer being used in place of the protein
solution during the entrapment step.
Several conditions were varied in this study to increase the amount of
entrapped protein. These conditions included the method that was used to isolate the
oxidized glycogen, the concentration of the protein that was used during the entrapment
method, and the mass ratio of the protein versus silica that was utilized. The entrapped
protein supports and control supports were suspended in pH 7.4, 0.067 M potassium
phosphate buffer and were downward slurry packed into 1.0 cm × 2.1 mm i.d. stainless
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steel columns. A pH 7.4, 0.067 M potassium phosphate buffer was used as the packing
solution. As the support slurry entered the column, the pressure was increased gradually
until it reached a maximum of 3500 psi and was held at this pressure for 50 min while
passing the pH 7.4 phosphate buffer through the column. The pressure was then decreased
gradually to avoid disturbing the packed support. The column was later taken off of the
packing system, and its assembly was completed. Before carrying out any experiments
with these supports, each column was placed in an HPLC system and pH 7.4, 0.067 M
potassium phosphate buffer was passed through the column at 0.5 mL/min for at least 1 h
or until a stable baseline was achieved.

2.2.4. Chromatographic methods
The application and elution buffer that was used in the chromatographic studies
with the entrapped HSA columns was pH 7.4, 0.067 M potassium phosphate [26,31-36].
The application and elution buffer for the work with the entrapped Con A columns was pH
5.0, 0.50 M sodium acetate that contained 1 mM calcium chloride and 1 mM manganese
chloride [37,38]. All columns were equilibrated with their corresponding buffer at 0.50
mL/min for at least 1 h before injections were made (Note: more time was required to reach
a stable baseline when the column was conditioned for the first time). The temperature
was maintained at 37 °C for the HSA columns and at 20 °C for the Con A columns, as well
as for their respective control columns, during these experiments. The injected analytes
were dissolved in the same application/elution buffers as were used on each of these
columns. The wavelengths used for detection were 307 nm for warfarin, 316 nm for MUM
or MUGA, and 205 nm or 220 nm for sodium nitrate.
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In the zonal elution studies, several sample concentrations and flow rates were
tested for use with each probe or analyte to find conditions in which the measured retention
factors remained constant even when making small changes in these parameters. The
sample volumes that were used were 5 µL or 20 µL. No significant variations in the
retention factors were seen when using the following conditions for the zonal elution
studies: flow rate, 0.50 mL/min; sample concentrations, 10-20 µM warfarin, 5-10 µM
MUM or MUGA, and 2.5-5.0 µM sodium nitrate. These conditions for providing linear
elution conditions and results that were independent of the flow rate agreed with previous
observations that have been made in prior studies with HSA columns [33,36,39,40].
The retention time for each injected solute was estimated by analyzing the
chromatograms with PeakFit 4.12 and fitting the data by using an exponentially-modified
Gaussian and half-Gaussian modified Gaussian (EMG+CMG) function, followed by
determination of each peak’s first statistical moment or centroid. All of the retention
factors were determined for data acquired over at least three injections on the entrapped
protein columns and control columns. The solutes that were used as non-retained markers
were sodium nitrate for the HSA columns and MUGA for the Con A columns. The extracolumn void time of the system was found by measuring the elution time of the nonretained solutes when a zero volume union was placed into the chromatographic system
instead of the column [39].
The protein content of each stationary phase was measured initially by using a BCA
protein assay [41,42]. An alternative method was also developed, as described later in this
chapter, that involved labeling some of the protein with fluorescein, entrapping this labeled
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protein, and then measuring the fluorescence of a slurry that was prepared with the
entrapped and labeled protein support.

2.3. RESULTS AND DISCUSSION

2.3.1. Initial measurement of protein content by the BCA assay
The protein coverage of the supports was first measured by a BCA assay. This
method is based on the ability of proteins to reduce Cu2+ to Cu+ in an alkaline solution (i.e.,
the biuret reaction), with the Cu+ then forming a complex with the BCA reagent to form a
colored complex that absorbs light at 562 nm [41,42]. The initial batches of the entrapped
HSA support that were made in this study gave only a small apparent protein content when
measured by this assay, as well as weak retention for warfarin on a column that contained
this support. An increase in the reaction volume that was used during the protein
entrapment did lead to some increase in the retention factor for warfarin, however, the
apparent protein content of the support was still small.
One major issue in these early experiments was that it was difficult to determine
the protein content of the supports by the BCA protein assay. This occurred because both
the control support and support containing the entrapped protein gave a high response in
this assay. It was hypothesized that this behavior was caused by the presence of the
hydrazide groups on the support which, like the peptide backbone of proteins, could reduce
Cu2+ to Cu+ in the BCA assay. The large response for the control support in this assay
created only small differences in the final absorbances that were measured for the supports
with entrapped proteins versus the control supports. This, in turn, produced high variability
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in the final results. To resolve this issue, a search was made for another method that could
be used to measure the protein content of these supports.

2.3.2. Measurement of protein content in supports by fluorescence
A method based on fluorescence was also developed and tested to estimate the
protein content of supports that were prepared through entrapment. This method involved
labeling a portion of the protein with fluorescein, entrapping this protein, and then
measuring the fluorescence of a slurry that contained the support with the entrapped and
labeled protein. A procedure for labeling HSA or BSA with FITC [43], was adapted for
this work, as based on directions provided by the manufacturer of the FITC reagent [44].
In this procedure, a solution containing 8.8 mg of the protein in 4 mL of freshly prepared
pH 9.0, 0.10 M sodium carbonate/bicarbonate buffer was combined with 1 mL of 1 mg/mL
FITC in the same buffer, giving a molar ratio for FITC vs. albumin of 20:1. This mixture
was stirred in the dark for 2 h at room temperature.
An Econo-Pac 10DG disposable desalting column was used to separate the
unreacted FITC from the fluorescein-protein conjugate and to carry out buffer exchange.
In this part of the procedure, a 3 mL portion of the reaction mixture containing the excess
FITC and the fluorescein-protein conjugate was applied to the desalting column and eluted
with pH 7.4, 0.010 M phosphate buffered saline, according to instructions by the supplier
of the column. The first yellow fraction (about 4 mL, and which contained the labeled
protein) was collected; this fraction was further purified by using an ultrafiltration tube
with a 30 kDa MW cutoff and pH 5.0, 0.10 M potassium phosphate buffer. The initial
volume of the sample plus the buffer in this tube was 3 mL. The centrifugation step for this
tube proceeded at 2.5 × 103 g and 25 °C until the volume of solution in the tube was reduced
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to 0.5 mL. The process of adding more buffer and centrifugation was repeated until no
free FITC from the original solution that held the fluorescein-protein conjugate was
detected, as based on absorbance measurements of the filtrate at 495 nm. Three filtration
cycles were necessary to complete this process.
The labeling ratio for the protein conjugate (i.e., the ratio of fluorescein-to-protein,
or F/P, in the final conjugate) was determined by making absorbance measurements at both
280 nm (for the protein) and at 495 nm (for the fluorescein), as well as for solutions
containing only the protein or FITC at these same wavelengths. When BSA was used in
this labeling method, the ratio of fluorescein-to-protein in the resulting conjugate was
determined to be 2.37 (± 0.10) mol/mol (n = 3).
To test for the response of the proposed fluorescence assay in the presence of silica,
several dilutions of an FITC-BSA conjugate were placed into a slurry containing 40 mg/mL
of diol-bonded silica in pH 7.4, 0.067 M potassium phosphate buffer. These solutions were
placed into a 96-well plate in 250 µL aliquots and measured for their fluorescence, using
495 nm as the excitation wavelength and 521 nm as the emission wavelength. As
demonstrated in Figure 2.5 (top), a linear response with a value for r2 that was greater than
0.98 was obtained for these results, along with a low response for the blank. In addition,
reproducible results were acquired for samples that contained up to 0.05 mg/mL FITCBSA. To investigate the effect of settling by the support over time, measurements were
taken after letting the slurry stand in the well plates from 1 min to 10 min. The response
for each slurry concentration did vary over time in this study, but the response was
consistent when this time was kept constant for all samples and standards.
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Figure 2.5

Typical results for a method based on fluorescence for measuring the protein
content of supports prepared through the entrapment of BSA-FITC. The
upper graph shows the response that was obtained for various slurry
concentrations of silica that contained entrapped BSA-FITC. The calibration
plot in the bottom shows the response that was obtained when various
amounts of FITC were added to a 0.4 mg/mL slurry of silica. The buffer used
in this study was pH 7.4, 0.067 M potassium phosphate buffer. Based on this
method, the protein content of the support containing entrapped and labeled
BSA was estimated to be 24 (± 3) mg of BSA-FITC/g silica.
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Fluorescense of BSA-FITC entrapment silica vs.
slurry concentration
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This assay was used to optimize the conditions for entrapping proteins such as BSA
or HSA in silica, as accomplished by using a preparation of FITC-BSA for the entrapment
process. This sample was originally employed under the same conditions as were initially
used to entrap HSA. The resulting slurry was diluted to minimize the effects of light
scattering by the support and to provide samples that gave measurements within the linear
range of the assay. Solutions containing commercial FITC-BSA or FITC-BSA that was
prepared in-house and the control silica were used to prepare the calibration plots. Slurries
of the entrapped BSA-FITC that had silica concentrations ranging from 1 to 10 mg/mL
gave signals of 5 to 60 fluorescence units and a linear response in this assay. Slurries that
were made with the control support or diol-bonded silica gave a background response of
less than 2 fluorescence units over the same range of slurry concentrations.

The

fluorescence measurements were taken within 30 s of placing the samples into the wells to
avoid any change in the signal over time (Note: only a small effect of time on the signal
was observed in this case because of dilute slurry concentrations that were being used).
Determination of the entrapped protein content by fluorescence was used for
monitoring the protein content that was obtained when using various entrapment conditions
for both FITC-BSA and FITC-HSA (Note: the FITC-BSA was made under the same
conditions as described for FITC-HSA). In the final conditions that were used for these
assays, slurries were made from the supports containing entrapped FITC-BSA or FITCHSA and were diluted to a slurry concentration that yielded a fluorescence signal between
20 and 50 units. A calibration curve was made using a slurry of the control support that
had the same silica concentration as the sample. The same preparation of the labelled
protein that was used for entrapment was also used to make the standards for the calibration
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plot. The best-fit lines for all the resulting calibration plots had r 2 values that were greater
than 0.98. An example of such a plot is given in the bottom of Figure 2.5.

2.3.3. Comparison of the fluorescence assay with thermogravimetric analysis
To further test the fluorescence assay, thermogravimetric analysis (TGA) was used
for measuring the protein content of several samples of HSA silica that had also been
analyzed by the BCA protein assay and the fluorescence method. TGA is a destructive
technique that monitors the loss in mass for a sample as the temperature of the sample is
increased [45]. The results are given in the form of a thermogram, or a plot of mass vs.
temperature. This technique is quite sensitive for detecting small differences in mass with
temperature, which makes it useful for studying changes in sample composition that occur
as a function of temperature [46,47].
The following conditions were found to be useful for analyzing the protein content
of silica by TGA. First, the sample was placed in a TGA pan and its mass was recorded
while going from room temperature to 110 °C at 5 °C/min. Second, this sample was held
at 110 °C for 20 min to eliminate any traces of water that were present and to condition the
sample; the mass was then again recorded and used as the “initial mass”. Third, the
temperature was increased from 110 °C to 650-850 °C at 20 °C/min while the mass was
recorded; the result that was obtained when the mass no longer changed with the
temperature was used as the “final mass”. During this process, nitrogen at a flow rate of
20 mL/min was used to purge oxygen from the analysis chamber.
The losses in mass that were measured by TGA for the silica that contained
entrapped proteins and for the control silica were compared. The difference in this mass
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should have represented the amount of protein that was entrapped in the silica, because the
control silica had no protein but was prepared with all other reagents being the same as
were used for the entrapment process. An HSA silica support and a control silica support
that were prepared by the Schiff base method were also analyzed by TGA for comparison
of their results with those obtained for the same materials with a BCA protein assay.
The thermogravimetric data were normalized and the percent mass loss for the
silica samples containing protein or for the control silica supports were calculated as shown
by Equation 2.1,
𝑃𝑟𝑜𝑡𝑒𝑖𝑛 % = (%𝑊𝑒1 − %𝑊𝑒2 ) − (%𝑊𝑐1 − %𝑊𝑐2 )

(2.1)

where %We1 and %We2 are the weight percent values for the supports that were
prepared by entrapment (or that contained immobilized protein) at the initial temperature
for the study (i.e., after conditioning the support at 110 °C) and at the final temperature that
was used for the analysis, respectively. The values of %Wc1 and %Wc2 in Equation 2.1 are
the weight percent values that were measured at the same initial and final temperatures for
the corresponding control support. As this equation indicates, the difference in these
masses should have corresponded to the amount of protein that was lost through
combustion from the entrapped protein support during the TGA analysis. The initial and
final temperatures that were used in this calculation were selected so that the weight of the
support was initially constant (i.e., after the support had been held at 110 °C), and the
weight had reached a plateau after being heated (i.e., which usually occurred after 650 °C).
The same temperatures were used for both the entrapped protein supports and the control
supports.
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Some examples of thermograms that were obtained for a control support and a
support that contained entrapped proteins are presented in Figure 2.6. Table 2.1 compares
the results that were obtained by the TGA method with those for the BCA assay and the
fluorescence method, as described in the previous section. As can be seen in this table,
there was a good agreement between the results that were obtained by the three methods.
These results offered additional evidence that the fluorescence method, or TGA, could be
used as an alternative to the BCA assay for measuring the protein content of supports that
were prepared through entrapment.

2.3.4. Purification of oxidized glycogen
Various factors were considered in an attempt to increase the amount of protein that
could be immobilized through the entrapment method. One of these factors was the way
in which the oxidized glycation was isolated after its oxidation with periodate and before
its use in the entrapment method. The oxidized glycogen that was to be used for entrapment
was initially purified by placing a 3 mL portion of the oxidized glycogen solution onto a
gel filtration column (i.e., an Econo-Pac 10DG disposable desalting column, 3.3 mL void
volume, 6 kDa exclusion mass). A pH 5.0, 0.10 M potassium phosphate buffer was next
added, as previously described for the purification of oxidized glycogen [28] and buffer
exchange, and by following the directions provided by manufacturer of this column.
However, this purification method appeared to give a low protein content in the entrapment
method, as described in Section 2.3.1.
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Figure 2.6

Typical results obtained by TGA for a support containing entrapped FITCBSA and a control silica. The experimental conditions are described in the
text.
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Table 2.1.

Protein content of various supports prepared under the same conditions but
that were measured by several methods.

Immobilization
method

1

Type of protein or analysis method, and protein content
(mg/g silica)
HSA,
TGA1

BSA-FITC,
Fluorescence2

Entrapment method

22.1

23.9 (± 2.9)

Schiff base method

35.3

HSA,
BCA assay2

30.7 (± 3.5)

These results were obtained for one set of samples of the protein supports (containing
HSA) and the control supports
2
This result is based on at least three replicate samples.
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To increase this protein content, the elution fraction from the gel filtration column
that had the highest amount of oxidized glycogen was determined by measuring the
absorbance at 280 nm for 1 mL portions of the collected fractions. Fractions 2-4 (with a
total volume of 3 mL) were found to have the highest absorbance and were used for
entrapment. However, no significant increase in the protein content of the entrapped
supports was achieved under these modified conditions. It was also observed that some
cloudiness started to appear in the collected and oxidized glycogen fraction after about two
days of storage at 4 °C. Allowing this solution to sit for one week resulted in extensive
precipitation. It is believed that this behavior indicated that there was still some periodic
acid left in the glycogen mixture, which continued to lead to further oxidation of the
glycogen and its cross-linking or aggregation over time.
To avoid these problems, an alternative method of purification for the oxidized
glycogen was examined based on ultrafiltration. In this method, a 4 mL portion of a
reaction mixture that contained oxidized glycogen and periodic acid in pH 5.0, 20 mM
sodium acetate buffer containing with 15 mM sodium chloride was placed into an
ultrafiltration tube with a MW cutoff of 30 kDa. This tube was centrifuged at 3 × 10 3 g
and 20 °C, with pH 5.0, 0.10 M potassium phosphate buffer being added as needed. The
volume of the solution in the tube was filled to the 5 mL mark with this pH 5.0 buffer
before each centrifugation cycle, and the centrifugation was continued until the solution
volume in the tube was 2.5 mL. This process was then repeated, following the addition of
more pH 5.0 buffer to the tube. During this process, some haziness was often observed in
the oxidized glycogen solution, which may have indicated the beginning of some
aggregation or cross-linking. To overcome this problem, the procedure was modified by
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carrying out three centrifugation cycles in the presence of water before the pH 5.0 buffer
was used. This new procedure involved at least seven centrifugation cycles, each requiring
10 to 15 min to complete. The purified oxidized glycogen solution that was obtained by
this method was used within two days of preparation and did not show any cloudiness over
at least one week of storage. This was the type of oxidized glycogen that was used in all
later work in this dissertation.

2.3.5. Size fractionation of oxidized glycogen
Glycogen is a branch-on-branch polysaccharide with a homogeneous branched
structure that is formed by α(1→4) linked D-glucose with α(1→6) branching at about every
8 to 12 glucose residues. Glycogen has an average degree of branching of 7-9% and an
average molar mass of 105 to 108 Da, with a broad size distribution in size that depends on
the type of animal from which the glycogen was obtained [48,49]. Experiments were
carried out to see if there were any molecules of oxidized glycogen that were too small to
be used as capping agents for porous silica during entrapment. Of particular interest were
glycogen molecules that had molecular weights under 300 kDa, due to the pore size of the
silica supports that were used in this study.
To study the effects of the presence or absence of these smaller glycogen molecules,
oxidized glycogen was prepared and purified by using a modified form of the ultrafiltration
method that was described in the previous section. This preparation was then labeled that
same day with LyCH (i.e., a hydrazide-containing dye that can couple with compounds
that have free aldehyde groups), according a method adapted from the literature for use
with oxidized glycoproteins [50-52]. Briefly, a 3 mg/mL solution of LyCH was prepared
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by dissolving this reagent in pH 6.5, 0.10 M potassium phosphate buffer and heating the
mixture to about 50 °C. A 17 mg portion of oxidized glycogen was purified by using an
ultrafiltration tube with a MW cutoff of 30 kDa and was exchanged through this process
into pH 6.5, 0.10 M potassium phosphate buffer. The final volume of this solution was 4
mL and its glycogen concentration was approximately 4.2 mg/mL.
For the labeling reaction, 1 mL of the oxidized glycogen solution was mixed with
1 mL of the LyCH solution for 2 h. The reaction mixture was purified by gel filtration to
remove the excess LyCH. The same type of gel filtration column that was used initially in
the purification of oxidized glycogen was used to remove the excess LyCH. The fraction
due to the first yellow band that eluted from this column contained unreacted LyCH; this
fraction was discarded. A second yellow band that corresponded to the labelled and
oxidized glycogen eluted between 14 and 22 mL and was collected.

Absorbance

measurements that were made at 428 nm on these fractions were used to monitor the elution
process. The LyCH-glycogen conjugate was further purified by ultrafiltration and the
buffer was exchanged with water by using a tube with a 30 kDa cutoff and the procedure
described in the previous section that used a series of washes with water.

The

centrifugation cycles were stopped when no yellow color and no absorbance at 428 nm was
detected in the filtrate, indicating that all of the excess and unreacted LyCH had been
removed from the oxidized glycogen solution. After this process, the yellow solution of
the LyCH-labelled oxidized glycation was diluted to 6 mL with water, and 3 mL of this
solution was transferred to an ultrafiltration tube with a 300 kDa cutoff. Water was added
to raise the volume of the solution in the tube to 6 mL, and this tube was centrifuged until
the solution in the tube reached 2.5 mL (see
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Figure 2.7).

The fraction of the labeled and oxidized glycogen that passed through the 300 kDa
cutoff membrane of the second ultrafiltration tube was found by using the absorbance
values and the volumes of the filtrate and retentate. The absorbance of the filtrate was
corrected by subtracting the absorbance of the filtrate from the tube with the 30 kDa cutoff,
which was used as a blank. The result indicated that only 2.1% of the oxidized glycogen,
as obtained from bovine liver, had sizes under 300 kDa. These results showed that the
molecular weight for most of the oxidized glycogen that was used for protein entrapment
was greater than or equal to 300 kDa. In related experiments, it was determined that the
process of washing and concentrating the oxidized glycogen solutions by ultrafiltration and
centrifugation was about three times faster on the tubes that had 300 kDa cutoff membranes
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vs. those with a 30 kDa cutoff. However, the 30 kDa filters were also acceptable for this
work and were used in the following studies.
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Figure 2.7

Ultrafiltration and centrifugation studies carried out with oxidized glycogen
that was labelled with LyCH and that had been previously purified by gel
filtration and ultrafiltration using a tube with a 30,000 Da MW cutoff
(MWCO). The image on the left show this solution before it was subjected
to ultrafiltration and centrifugation using tubes with 300,000 Da or 30,000
Da cutoff values; the image on the right shows the result after the
centrifugation/ultrafiltration step that was performed for measuring the
fraction of the glycogen that was smaller than 300,000 Da.
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2.3.6. Optimization of protein entrapment based on measurements of protein
content
Several experiments were next carried out to maximize the final content of proteins
such as HSA that could be immobilized by entrapment within silica. This work was
initially carried by using normal HSA and FITC-labelled BSA or HSA as model proteins.
Modifying and changing the purification method for the oxidized glycogen from gel
filtration to ultrafiltration, as described in the previous section, provided a 1.8-fold increase
in the protein content that could be obtained through entrapment for FITC-BSA, as shown
in Table 2.2. This improvement can be explained by the multiple washing steps that were
now used in the ultrafiltration method, which should have helped to more effectively
eliminate periodic acid after the oxidation process. This, in turn, should have avoided any
further reaction of this reagent with glycogen, and prevented any aggregation or crosslinking of the oxidized glycogen before it could react with the hydrazide-activated silica.
Two other changes that were made in the entrapment procedure, as indicated in
Table 2.2, involved decreasing the volume of solution that was used in the entrapment
reaction (e.g., from 2.0 mL to 1.7 mL) and introducing a step in which the protein was
allowed to incubate with the hydrazide-activated silica before the oxidized glycogen was
added. This combination of changes helped to increase the protein content by 2.5-fold
versus the initial conditions. Lowering the solution volume further to 1.0 mL during
entrapment gave a 3.9-fold increase in the final protein content for HSA. Increasing the
protein/silica amount that was used for entrapment to 400 mg/g silica for HSA plus
decreasing the solution volume to 0.72 mL gave an apparent increase of 3.2-fold in the
protein content when compared to the initial reaction conditions (Note: this latter change
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may not have been statistically significant due to the large variation in the measured protein
content that was obtained when using the BCA assay). Decreasing the solution volume
further to 0.2 mL gave a 6.4- to 7.4-fold increase in protein content for the FITC-labeled
HSA and BSA when compared to the results that were obtained with the initial reaction
conditions for FITC-BSA.

2.3.7. Optimization of protein entrapment based on retention factor measurements
The conditions that could be used for entrapment were also optimized by using
HSA as a model protein and by comparing the amount of active protein in the supports, as
determined through retention factor measurements. In this approach, columns that were
prepared with each type of support, and its control support, were compared for their
retention of warfarin, which is a drug that has well-characterized binding to HSA. In this
method, the retention time (tr) was measured for warfarin on both a column containing
entrapped HSA and on a control column. The value of the retention factor (k) on each type
of column was then calculated according to the following expressions:
𝑘1 =

(𝑡𝑟1 −𝑡𝑚1 )
(𝑡𝑚1 −𝑡𝑣 )

(2.2)
𝑘 = 𝑘1 − 𝑘2

𝑘2 =

(𝑡𝑟2 −𝑡𝑚2 )
(𝑡𝑚2 −𝑡𝑣 )

(2.3)

(2.4)

where k1 and k2 are the retention factors for warfarin on the columns containing the
entrapment protein or control support, respectively; tr1 and tr2 are the retention times for
warfarin on these columns; tm1 and tm2 are the void times of these columns (e.g., as
measured by using the elution times of a non-retained solute); and tv is the void time of the
system (e.g., as measured by injecting a non-retained solute with no column present in the
system).
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Table 2.2.

Protein content obtained under various conditions when using the
entrapment method

Experiments - Initial conditions for
entrapment and changes made in these

Type of protein

conditions

Protein content
(mg/g silica)1

1 Initial conditions:
Total volume,2 2.0 mL
FITC-BSA

5.9 (± 0.2)

FITC-BSA

10.6 (± 0.6)

FITC-BSA

15 (± 2)

HSA

23 (± 11)

Con A

44 (± 15)

HSA

19 (± 10)

6 Total volume2 decreased from Expt. 5 to 0.2

FITC-HSA

39 (± 3)

mL and HSA/silica ratio kept at 400 mg/g

FITC-BSA

44 (± 3)

HSA/silica ratio, 100 mg/g
Oxidized glycogen purified by gel filtration
2 Oxidized glycogen purification method
changed from gel filtration to ultrafiltration
3 Total volume2 decreased from Expt. 2 to 1.7
mL; Pre-incubation step for protein with the
support (4 h) added to the entrapment procedure
4 Total volume2 changed from Expt. 3 to 1 mL
5 Total volume2 decreased from Expt. 4 to 0.72
mL; HSA/silica ratio increased to 400 mg/g

1

These results are the average for three measurement of the protein content by using the

fluorescence for the fluorescein-protein conjugates or the BCA assay for the unmodified
HSA or Con A. The numbers in parentheses represent a range of ± 1 S.D.
2

This value refers to the total volume of the solutions that were added to the support.
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The retention factor for the control column was used to account for any non-specific
interactions that warfarin may have had with the support. By subtracting this value from
the retention factor that was measured on the entrapped protein column, as indicated in
Equation 2.2, a value for the corrected retention factor was obtained that should have been
related only to the interactions of warfarin with the immobilized HSA. In this study, these
measurements were made by using 1.0 cm × 2.1 mm columns that contained the entrapped
protein support or the control support.
Table 2.3 shows how the corrected retention factor for warfarin changed when
examining entrapped HSA columns that were prepared by using five sets of entrapment
conditions. The first column of experimental data (i.e., Experiment 1) shows the results
that were obtained after 1) the purification method for glycogen had been changed from
gel filtration to ultrafiltration, 2) an initial incubation time for the protein with the support
of 4 h had been introduced, and 3) the solution volume had been reduced from 2.0 mL to
1.0 mL. This corresponds to the same set of conditions that were present for Experiment
4 in Table 2.2.
Further modifications were then made in the entrapment procedure. Examples of
modifications that were examined included decreasing the total reaction volume,
increasing the concentration of the protein solution, and increasing the relative amount of
the protein with respect to the support. A vortex mixer was used to allow the solution
volumes to be kept below 0.72 mL in Experiments 2-5, but this volume was decreased to
values as low as 0.2 mL (see Experiments 4-5). The concentration of protein that was
used for the entrapment process increased from the reference amount of 8 mg/mL in
Experiment 1 to a value of 100 mg/mL in Experiment 5. The relative amount of protein
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with respect to the support was also increased from the value of 100 mg/g in Experiment 1
to values that ranged from 120 to 400 mg/g in the other experiments.
Overall, these changes in the entrapment conditions allowed an increase to be
obtained in the corrected retention factor for warfarin from a value of 3.0 in Experiment 1
to a value of around 50 in Experiment 5. Some trends that were noted in these experiments
are summarized in Figure 2.8. For instance, a 16-fold increase in the retention factor for
warfarin was seen as the concentration of HSA that was used for entrapment was increased
by 13-fold. Also there was a 12.5- to 16-fold increase in this retention factor as the ratio
of HSA-to-silica was increased by 3.3- 4.0-fold.
In the final conditions that were selected for the entrapment method, the hydrazideactivated silica that was produced from a 50 mg batch of diol silica was transferred to a 2
mL vial, spun and decanted. The remaining reaction was carried out at room temperature
(about 20 °C) and used a programmable vortex mixer that could run unattended to combine
and mix the reagents with the silica. In the case of HSA, the activated support was mixed
with 100 µL of 200 mg/mL HSA in pH 5.0, 0.10 M potassium phosphate buffer, plus
another 100 µL of the same buffer with no protein present (Note: the additional buffer was
used to obtain the same overall HSA concentration as was later used during the entrapment
step). This slurry was mixed for 4 h on the programmable vortex mixer, with the excess
solution then being decanted from the support. Second, 100 µL of 200 mg/mL HSA in pH
5.0, 0.10 M potassium phosphate buffer and 100 µL of 8.5 mg/mL oxidized glycogen in
pH 5.0, 0.10 M potassium phosphate buffer were added (total reaction volume, 0.20 mL;
HSA concentration, 100 mg/mL; oxidized glycogen concentration, 4.25 mg/mL), and the
slurry was mixed for another 16 h at room temperature using the vortex mixer. To make
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the control support, pH 5.0, 0.10 M potassium phosphate buffer was used in place of the
protein solution. Finally, 50 µL of a 1 mg/mL oxalic dihydrazide solution in pH 5.0, 0.10
M potassium phosphate buffer was added to the slurry, and the mixing was continued for
another 1 h.
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Table 2.3. Corrected retention factors for warfarin measured on 1.0 cm × 2.1 mm
columns containing HSA entrapped within silica under various conditions
Experiment1
Entrapment conditions
1

2

3

4

5

1

0.72

0.3

0.2

0.2

80

88

167

250

250

8

35

20

40

100

100

396

120

160

400

1.2

1.3

3.0

4.2

3.75

15

15

18

17

15

3.0
(± 0.6)

15.8
(± 1.4)

4.0
(± 0.9)

9.5
(± 2.6)

49.9
(± 7.9)

Total volume (mL)
Mass of silica
(mg/mL)2
Concentration of HSA
(mg/mL)3
Mass ratio of
HSA/silica (mg/g)4
Concentration of
oxidized glycogen
(mg/mL)

3

Mass ratio of oxidized
glycogen/silica (mg/g)4
Retention factor5
1

The results for experiments 1, 2 and 5 in this Table were obtained with the same

entrapment conditions as the last three experiments for HSA that are listed in Table 2.2.
2

This value is the equivalent mass of diol-bonded silica that was present per unit of

volume of the reaction mixture.
3

These concentrations are based on total volume of all solutions that were added.

4

These mass ratios are based on the equivalent mass of diol-bonded silica that was used.

5

These results are the averages of two or three determinations. The value for Experiment
5 is the average for two different batches of the entrapped HSA supports.
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Figure 2.8

Variation in corrected retention factor (k) measured for warfarin on columns
containing entrapped HSA that were prepared by varying the concentration
of HSA that was used for entrapment or the relative amount of HSA versus
the support that was used for entrapment. The errors bars represent a range
of ± 1 S.D.
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2.4. CONCLUSIONS
Several factors were examined to maximize the amount of proteins such as BSA
and HSA that could be immobilized onto porous silica by entrapment. Some of the
conditions that were modified were the purification method that was used for the oxidized
glycogen, the concentration of protein that was used in the reaction mixture for entrapment,
and the ratio of the protein vs. support that was used for entrapment. Alternative ways of
monitoring the total amount of protein or active protein in the resulting supports were also
considered.

Examples of these methods included the use of fluorescence and

thermogravimetric analysis. In the following chapter, the measurement of retention factors
with probe compounds for the entrapped proteins will be explored as another method for
determining the protein content.
It was found that improvements in the protein content could be achieved by
changing several parameters. This included altering the purification method from gel
filtration chromatography to ultrafiltration, using a pre-incubation step for the protein with
the support, increasing the concentration of HSA in the entrapment method, and decreasing
the solution volume in the reaction mixture. Changing these conditions gave up to a 7.4fold increase in the amount of entrapped protein that could be obtained versus the initial
reaction conditions.

Increasing the concentration of the protein and increasing the

protein/support mass ratio gave an even further increase in the apparent protein content, as
represented by an increase of 16-fold in the retention factor for warfarin on entrapped HSA
columns. This entrapment procedure can be adapted for use with other proteins or supports
by using methods similar to those described in this chapter.
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CHAPTER 3.
OPTIMIZATION OF A FLOW-BASED FORMAT FOR
ENTRAPMENT

3.1.

INTRODUCTION
High-performance affinity chromatography (HPAC) combines the high specificity

of affinity chromatography with the instrumentation of HPLC to provide a fast and high
throughput approach for biochemical separations [1-5]. Several rigid supports with high
mechanical stability and good mass transfer properties are available for use in HPAC, such
as porous silica beads, perfusion supports, polymer-based monoliths, and silica monoliths
[6-11]. Chromatographic columns that contain porous silica supports and immobilized
proteins or antibodies as affinity ligands have all been used in the past for studying
biological interactions [12-19].
One method that has been widely used for the immobilization of proteins to
supports that are used in HPAC is covalent attachment. One disadvantage of this approach
is that it suffers from effects such as multisite attachment and steric hindrance, which may
lead to some loss in the apparent activity of an immobilized binding agent [20-22]. In the
previous chapter, an alternative method to covalent immobilization based on entrapment
was optimized to produce affinity supports with high protein contents. This technique
offered the potential advantage of providing an immobilized protein or binding agent that
was fully active and in a soluble form for interacting with drugs and other small analytes
that may be applied later to the affinity column [23-26].
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In this chapter, an alternative method for immobilizing proteins by entrapment
within HPLC-grade porous silica is discussed. Ways to use this approach to further
increase the protein content of affinity supports that are prepared through entrapment are
also explored. The primary method that will be examined will be based on the entrapment
of proteins by recirculating these and the other reagents through hydrazide-activated silica
that has previously been packed in a column. This flow-based format should provide the
smallest possible volume that can be occupied by the silica particles during the entrapment
process. It is expected that this reduced volume should promote better contact of the
proteins with the surface and pores of the particles while the active aldehyde groups on the
capping agent (i.e., oxidized glycogen) are reacting with hydrazide groups on the particles.
This, in turn, should result in larger amounts of protein that can be entrapped when
compared to the slurry-based method that was described in the previous chapter. The oncolumn method of entrapment that will be examined in this chapter should also be more
amenable for automation than the slurry-based method. Finally, this on-line format has the
potential for reducing the amount of protein and reagents that are required for entrapment,
which may make it possible to apply this technique to other types of affinity ligands.

3.2.

EXPERIMENTAL SECTION

3.2.1. Reagents
The human serum albumin (HSA, essentially fatty acid free, purity ≥ 96%),
concanavalin A (Con A, type V, lyophilized powder, purity ≥ 99 %), glycogen (from
bovine liver, type IX; total glucose ≥ 85%, dry basis), racemic warfarin (purity ≥ 98%), Rwarfarin (purity ≥ 97%), carbamazepine (purity ≥ 98%), 4-methylumbellipheryl α-D-
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mannopyranoside (MUM, purity ≥ 96%), 4-methylumbellipheryl α-D-galactopyranoside
(MUGA, purity ≥ 98%), and periodic acid reagent (H5IO6, purity 99%) were purchased
from Sigma-Aldrich (St. Louis, MO, USA). The Nucleosil Si-300 silica (7 m particle
diameter, 300 Å pore size, 100 m2/g surface area) was obtained from Macherey-Nagel
(Düren, Germany). All other chemicals were of the purest grades available. All buffers
and aqueous solutions were prepared using water from a Nanopure system (Barnstead,
Dubuque, IA, USA) or a MilliQ Advantage 10 system (EMD Millipore Corporation,
Billerica, MA, USA). The buffers were filtered through 0.20 μm GNWP nylon membranes
from Millipore (Billerica, MA, USA) and were degassed by sonication under vacuum for
at least 20 min prior to use.

3.2.2. Apparatus
The chromatographic system consisted of two 1200 isocratic pumps from Agilent
(Santa Clara, CA, USA), a Series 200 UV-Vis detector and a vacuum degasser from Perkin
Elmer (Waltham, MA, USA), a Rheodyne LabPro valve (Cotati, CA, USA) equipped with
a 5 µL or 20 µL sample loop, and a series 1200 autosampler from Agilent. An Isotemp
9100 circulating water bath (Fisher Scientific, Pittsburgh, PA, USA) and a water jacket
from Alltech (Deerfield, IL, USA) were used for temperature control of the columns. The
chromatographic data were collected and processed using LabView 8 software (National
Instruments, Austin, TX, USA). The chromatograms were analyzed using PeakFit 4.12
(Systat Software, San Jose, CA, USA).
Two PHD Ultra syringe pumps (Harvard Apparatus, Holliston, MA, USA) were
used for the on-column entrapment method. A Pack-in-a-Box system (ChromTech, Apple
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Valley, MN, USA) was used for packing the supports into columns.

A UV-160A

spectrophotometer (Shimadzu, Kyoto, Japan) was used for the BCA protein assay.

3.2.3. Preparation of columns containing entrapped proteins
Diol silica was prepared from Nucleosil 300-7 silica by following a previous
procedure [1]. This support was then dried at 60 °C and stored in a desiccator. Portions
of this support (i.e., 50 mg batches of the diol silica) were further treated, as described
previously, to produce hydrazide-activated silica [1].

Each batch of the hydrazide-

activated silica was washed with pH 7.4, 0.067 M potassium phosphate buffer and
downward slurry packed into a 1 cm × 2.1 mm i.d. stainless steel column with the same
type of 7.4 buffer acting as the packing solution. In order to ensure homogeneous packing,
a slurry of the support was made with 5 mL of the pH 7.4 buffer, which was added to the
reservoir of the packing system after the column was attached to the bottom; this was
followed by a step where an additional 15 mL of the 7.4 buffer was used to fill the rest of
the reservoir. The packing was then begun by flowing the buffer and slurry at 3.0 mL/min.
The packing pressure and the flow were gradually increased over 10-15 min until reaching
a maximum pressure of 3400 psi (23.4 MPa). After 40 min, the pressure was gradually
relieved for 10-15 min to avoid disturbing the chromatographic support in the column.
The columns packed with hydrazide-activated silica were used for the on-column
entrapment of proteins in the presence of solutions of the desired protein and oxidized
glycogen. The reagents that were used for preparing the entrapped protein supports, the
proportions in which these reagents were combined, and the reaction times that were used
were the same as described in Chapter 2 [25]. In this chapter, a flow-based and on-column
entrapment approach was explored as an alternative to the previous method that was based
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on a reaction slurry. The conditions that were used for this modified entrapment approach
are described in the Results and Discussion section.

3.2.4. Chromatographic methods
The application and elution buffer that was used for the chromatographic studies
with HSA was pH 7.4, 0.067 M potassium phosphate. This same buffer has been used in
previous studies with HSA to provide physiological conditions for drug-protein binding
studies [13,27-32]. In the work with Con A, the application/elution buffer was pH 5.0,
0.50 M sodium acetate that contained 1 mM calcium chloride and 1 mM manganese
chloride to ensure optimum activity for the Con A, according to conditions reported in
previous studies [33,34].

The equilibration conditions and temperature of the

chromatographic studies were the same as described in Chapter 2. The wavelengths used
for detection were 307 nm for warfarin, 285 nm for carbamazepine, 280 nm for Ltryptophan, 316 nm for MUM and MUGA, and 205 nm or 220 nm for sodium nitrate.
In the zonal elution studies, each analyte was dissolved in the desired application
buffer and a sample volume of 5 µL or 20 µL was placed into the system by using an
injection valve. The concentrations of the analytes that were used in these experiments
were selected so that linear elution conditions were present. These conditions were
determined and confirmed by making several injections at various sample concentrations
to ensure that sample conditions were used over which the retention factor did not change
(at the 95% confidence level) with the concentration of the injected analyte [29,32,35,36].
The final sample concentrations that were used were 10-40 µM for each injected analyte
or probe and 2.5-5 µM for sodium nitrate. The flow rates that were used for measuring the
retention factors of these compounds were between 0.2 and 0.5 mL/min, with no significant
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difference been seen at the 95% confidence level in the results that were obtained over this
range of flow rates.
The retention times for each injected solute were found by carrying out a non-linear
fit with PeakFit 4.12 and by using an exponentially-modified Gaussian and half-Gaussian
modified Gaussian (EMG+CMG) function. The retention time or elution time was
estimated by using the first statistical moment of the fitted peak (i.e., the centroid). At least
three injections were done under each set of conditions for each solute and column. A
sodium nitrate solution was injected for determining the void time of each column. The
average retention factor and standard deviation of each solute on each entrapment column
were calculated. Injections of each solute on a control column were also made to correct
for non-specific binding, as explained in Section 2.3.7. These non-specific interactions
accounted for less than 1% of the overall retention for warfarin and less than 2% for
MUGA.

3.3.

RESULTS AND DISCUSSION

3.3.1. Optimization of the on-column entrapment method
The on-column entrapment method was initially carried out by using one syringe
pump, where two 1 mL plastic syringes were placed and connected to columns that were
packed with hydrazide-activated silica. Tubing was connected to each column and directed
to 2 mL vials. This system is shown in Figure 3.1(a). One column was used for the
entrapment reaction with the desired protein and the other was used to prepare a control
column that did not contain the protein (e.g., HSA in the initial studies with this method).
The reagents were dissolved in pH 5.0, 0.10 M potassium phosphate buffer and recirculated
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through the columns at 50 µL/min. When making the entrapped protein column, 0.8 mL
of 20 mg/mL HSA was recirculated through this column for 4 h, with the flow direction
being changed every three minutes. The solutions in the syringes were changed to 0.8 mL
of a mixture of 20 mg/mL HSA and 4.2 mg/mL oxidized glycogen, and the recirculation
was continued for 16 h. Finally, 200 µL of a solution containing 1 mg/mL oxalic
dihydrazide was mixed with the other reactants and the reaction was allowed to continue
for another hour under the same recirculation conditions. For the control column, the HSA
solutions were replaced with pH 5.0, 0.10 M potassium phosphate buffer.
The immobilization method with one syringe pump had some issues with bubble
formation in the HSA solutions and the formation of a void region in the syringes, which
was most noticeable in the syringe that was connected to the entrapped protein column. It
was found that atmospheric pressure was not enough to keep the solutions going through
columns when the syringes were used to draw the solutions from the collecting vials. The
higher viscosity of the solution with HSA made this problem more noticeable for the
entrapped protein column. As a result, bubbles formed in the syringe and created a
situation in which sometimes little or no protein solution was withdrawn by the syringe.
To achieve a better delivery of the reagents through the column, it was necessary to
periodically stop the delivery and refill the syringe with the solution from a collection vial.
When the retention factor for racemic warfarin was measured for such a column, the result
was 19 (± 2), where the value in parentheses represents one standard deviation for three
replicate injections that were made onto the same column.
A second column containing entrapped protein was made by using 40 mg/mL HSA,
with most of the other conditions being kept the same as in the previous study. The flow
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rate was reduced to 20 µL/min in an attempt to reduce bubble formation during the
entrapment process. A retention factor for warfarin of 82 (± 4) was achieved when this
second type of column was compared with its control column. This experiment indicated
that the use of a higher protein concentration during the entrapment process and the use of
an improved reagent delivery system gave a significant increase in the amount of protein
that was entrapped. However, it was still desirable to find a way to make the entrapment
conditions easier to control and to make this process more fully automated.
In the next phase of this study, the columns were each connected to two syringe
pumps that were equipped with 250 µL syringes. These pumps were synchronized to
recirculate a solution through the columns, with one syringe infusing a solution while the
other was used to withdraw the same solution. A diagram of such a system is given in
Figure 3.1(b). A picture of the entrapped protein columns and control columns when they
were attached to the syringe pumps in this system is provided in Figure 3.1(c). The volume
of solution that was used in each syringe was 200 µL, and the syringes were used to infuse
or withdraw 75 µL of this solution each cycle at a flow rate of 20 µL/min. A stop time of
1 min was included in this program between each change in direction of syringe movement
to allow the solution to completely go through the column and relieve any pressure buildup
before changing the direction of solution application. The solutions in this system could
be circulated through the columns without the formation of bubbles or foam, and the system
could be left unattended during the entrapment reaction. With this system, columns were
prepared by using concentrations of HSA that ranged from 12.5 to 100 mg/mL, as were
used to study the effect of protein concentration on the amount of protein that could be
entrapped by this immobilization method.
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The final entrapment procedure involved the use of the two-syringe system for 4 h
to apply a solution that first contained only the protein dissolved in pH 5.0, 0.10 M
potassium phosphate buffer; this was followed by the application of a mixture of the protein
and 4.2 mg/mL of oxidized glycogen in the same buffer for 16 h. Finally, a portion of 200
µL of 1 mg/mL oxalic dihydrazide in the same buffer was added to the reaction mixture
and the solution delivery was continued for another 2 h at room temperature. A control
column was made under the same conditions but with the solution of HSA being replaced
with an equal volume of pH 5.0, 0.10 M potassium phosphate buffer.
Immediately after this reaction was finished, the column was connected to an HPLC
pump and pH 7.4, 0.067 M potassium phosphate buffer was applied at 0.5 mL/min for 1 h
to wash away the excess reactants (e.g., any unreacted oxidized glycogen or oxalic
dihydrazide, and any remaining non-entrapped HSA).
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Figure 3.1 (a) Diagram of the on-column entrapment method with one syringe pump or
(b) two syringe pumps, and (c) an image of the on-column entrapment system
with two syringe pumps. The concentrations of protein and oxidized glycogen
in pH 5.0, 0.10 M phosphate buffer, the volume of the solutions that were used
and the flow rate are all indicated. Other entrapment conditions are given in
the text.
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The dual-syringe entrapment system was used to make several columns that
contained entrapped HSA or Con A to study the effects of the protein concentration in the
reaction mixture on the protein content of the resulting support. Examples of some
chromatograms and retention factors that were obtained for R/S-warfarin on columns that
were made by entrapment and using various concentrations of HSA are shown in Figure
3.2. The results for a column that was made by using the slurry entrapment method and
100 mg/mL of HSA are also included in this figure for comparison. For these HSA
columns, a 1.7-fold increase in the retention factor for R/S-warfarin occurred when going
from conditions that used 12.5 to 25 mg/mL HSA during the entrapment process. An
increase of 6.3% was seen in going from using 25 to 50 mg/mL HSA during entrapment.
These results indicated that an on-column entrapment method using 25 mg/mL HSA was
probably the most efficient and cost effective approach for entrapping this protein under
this given set of conditions.
These data were also used to compare the results obtained with the slurry method
vs. entrapment. In the slurry method, a 0.4 mL portion of 100 mg/mL HSA was used to
make the column, or a total of 40 mg protein. The on-column method only needed 0.4 mL
of 25 mg/mL HSA to make a column of the same size, or the equivalent of 10 mg protein,
and the retention factor that was obtained for warfarin increased by 1.5-fold (or was about
50% higher). Thus, the on-column method based on 25 mg/mL HSA was also a more
efficient and cost-effective approach for entrapment than the slurry method under this set
of conditions.
Some chromatograms and retention results that were obtained for Con A columns
that were prepared by the on-column method and slurry method are shown in Figure 3.3.
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Figure 3.2

Chromatograms and retention factors obtained for R/S-warfarin on columns
containing entrapped HSA and made by the slurry method or the on-column
method and using various protein concentrations in the reaction mixture.
Conditions: sample, 40 µM R/S-warfarin; column size, 1.0 cm × 2.1 mm
i.d.; flow rate, 0.50 mL/min; temperature, 37 ºC. The values in parentheses
represent a range of ± 1 S.D. (n = 3-4).
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Figure 3.3

Chromatograms and retention factors obtained for MUM on columns
containing entrapped Con A that were prepared by various methods and
reaction conditions.

The bottom chromatogram shows the results for

MUGA, which does not bind to Con A, and which was used to measure the
void time of the Con A columns. Conditions: samples, 10 µM MUM or 10
µM MUGA; column size, 1.0 cm × 2.1 mm I.D.; flow rate, 0.50 mL/min;
temperature, 20 ºC. The values in parentheses represent a range of ± 1 S.D.
(n = 3).
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The solubility of Con A limited the concentrations that could be used with the
protein for the entrapment process, but an increase of over two-fold in the retention factor
for MUM was seen when going from columns that were made using 1 mg/mL to 5 mg/mL
Con A (Note: at this later concentration, some of the Con A started to precipitate, and it
was necessary to filter this solution before using it for entrapment). The column that was
prepared by using 1 mg/mL Con A in the on-column entrapment method gave a retention
factor for MUM that was 1.2-fold higher than what was seen for the column that was made
using the same concentration of Con A in the slurry entrapment method. The column that
was made using 5 mg/mL Con A for on-column entrapment gave 2.6-fold higher retention
for MUM than the column that was made by the slurry method and using 1 mg/mL Con A.

3.3.2. Estimation of protein content following on-column entrapment
In the on-column method, the entrapment is performed directly on the column and
it is not possible to analyze the protein directly on the support by means such as absorbance,
fluorescence or a standard protein assay. However, it could be possible to estimate the
content of the active protein in the resulting column by conducting zonal elution
experiments in which solutes are injected that have known interactions and association
equilibrium constants (Ka) for these proteins. This latter approach was employed in this
study.
One feature that makes the entrapment technique suitable to this type of assay is
the fact that the protein is immobilized without covalent linkage to the support [16,25]. As
a result, the active sites of the protein should be fully active and available to an injected
probe that is able to enter the support and bind to these sites. Under these conditions, the
retention factor that is measured for the injected probe (k) can be related to the strength of
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the probe-protein interaction and the amount of protein in the column through the following
relationship [16,24,37].
𝑘 = (𝑛1 𝐾𝑎1 + 𝑛2 𝐾𝑎2 + ⋯ 𝑛𝑛 𝐾𝑎𝑛 )𝑚𝐿𝑡𝑜𝑡𝑎𝑙 /𝑉𝑚

(3.1)

were mLtotal represents the total moles of binding sites for the probe in the column, and Vm
is the column void volume. The term in parentheses is a number-weighted sum of the
association equilibrium constants for all of the binding sites that are involved in the probeprotein interaction, where ni is the relative number of moles of binding site i per mole of
protein, and Kai is the association equilibrium constant of the probe at binding site i. This
equation also assumes that all the binding sites for the probe are independent of each
another [16,24,37].
For the case of probe compounds that have only a single binding site on a protein
(e.g., as is the case for warfarin and carbamazepine with HSA) [16,29], Equation 3.1 can
be rewritten in the form shown in Equation 3.2 [16].
𝑘 = 𝐾𝑎

𝑚𝐿𝑡𝑜𝑡𝑎𝑙
𝑉𝑚

(3.2)

In this case n = 1 for the probe (e.g., warfarin), and the ratio mLtotal/Vm represents
the total concentration of protein that is immobilized or entrapped in the column [12,13,16].
If the retention factor is also corrected for any non-specific binding that may be occurring
with the support, this corrected value can be used with Equation 3.2 to estimate the
concentration or total moles of protein in the column.
The protein contents for columns containing entrapped HSA were estimated by
using carbamazepine or warfarin as the injected probes.

The following association

equilibrium constants have been previously reported for the interactions of these drugs with
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HSA at pH 7.4 and 37ºC: carbamazepine, 5.4 (± 0.2) × 103 M-1; R-warfarin, 2.1 (± 0.2) ×
105 M-1; and racemic warfarin, 2.3 (± 0.4) × 105 M-1, where this value is the average of the
values for R- and S-warfarin [29,30,32]. The retention measurements that were made for
all of these drugs were also carried out at pH 7.4 and 37ºC, along with a flow rate of 0.2 or
0.5 mL/min. Table 3.1 shows the corrected retention factors that were obtained with these
probes on columns that were made by using on-column entrapment method and various
concentrations of HSA. The protein contents that were estimated from these results are
shown in Table 3.2.
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Table 3.1. Corrected retention factors measured for several probe compounds that were
injected onto HSA columns that were prepared by the on-column entrapment method and
using various concentrations of HSA in the reaction mixture 1
Type of entrapment method
and HSA concentration
Slurry method, 100 mg/mL
HSA
On-column method, 12.5
mg/mL HSA
On-column method, 25 mg/mL
HSA
On-column method, 40 mg/mL
HSA2
On-column method, 50 mg/mL
HSA
On-column method, 100
mg/mL HSA
1

Corrected retention factor, k
Carbamazepine

R-Warfarin

R/S-Warfarin

0.95 (± 0.12)

39.5 (± 4.4)

37.6 (± 5.2)

1.42 (± 0.20)

45.1 (± 7.0)

42.4 (± 1.0)

1.65 (± 0.20)

61.1 (± 4.4)

68.2 (± 3.8)

1.98 (± 0.24)

69.0 (± 5.7)

65.2 (± 2.9)

1.91 (± 0.11)

73.9 (± 4.5)

75.6 (± 3.5)

5.75 (± 1.01)

196.1 (± 5.4)

227.8 (± 5.4)

The results for an HSA column that was prepared by the slurry method and using 100 mg/mL HSA

is included in this table for reference. All of the retention factors in this table were measured at
0.5 mL/min and 37 °C. The numbers in parentheses represent a range of ± 1 S.D., as obtained for
at least two or three injections per column; the only exception was for R/S-warfarin, in which two
or three columns were used and the value that is given is the combined average of the retention
factors for these columns.
2

This type of support was prepared by using only one syringe pump.
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Table 3.2. Protein content measured by using the retention factors for several probe
compounds that were injected onto HSA columns that were prepared by the on-column
entrapment method and using various concentrations of HSA in the reaction mixture1

Type of entrapment

Protein content (mg/g silica)1

method and HSA
concentration
Slurry method, 100
mg/mL HSA
On-column method,
12.5 mg/mL HSA
On-column method,
25 mg/mL HSA
On-column method,
40 mg/mL HSA
On-column method,
50 mg/mL HSA
On-column method,
100 mg/mL HSA

1The

Carbamazepine

R-Warfarin

R/S-Warfarin

Average

20.7 (± 5.7)

22.1 (± 6.3)

19.2 (± 6.3)

20.7 (± 3.5)

23.5 (± 7.1)

19.2 (± 6.2)

20.9 (± 6.4)

21.2 (± 3.8)

34.0 (± 8.9)

32.3 (± 8.4)

32.9 (± 9.7)

33.1 (± 5.2)

39.3 (± 10.4)

35.2 (± 9.4)

30.4 (± 9.0)

35.0 (± 5.6)

45.9 (± 10.7)

34.3 (± 8.8)

40.0 (± 11.5)

40.1 (± 6.0)

126 (± 37)

114 (± 28)

121 (± 34)

120 (± 19)

conditions are the same as in Table 3.1. The numbers in parentheses represent a

range of ± 1 S.D., as obtained for at least three injections per column. The protein content
was calculated by using molar mass of 66.4 kDa for HSA, the volume of the column, and
a packing density for silica of 0.45 g/cm 3. A 1:1 binding model was used along with the
following association equilibrium constants: carbamazepine: 5.4 (± 0.2) × 103 M-1 [29], Rwarfarin, 2.1 (± 0.2) × 105 M-1; racemic warfarin, 2.3 (± 0.4) × 105 M-1, where this last value
is the average of the values for R- and S-warfarin) [32].

90
The protein content that was obtained through this process for the HSA column that
was made by the slurry entrapment method was compared to the result that was estimated
for the same type of support when using a protein assay. In this case, the protein content
was also estimated by using fluorescence measurements and a support that had been
prepared under the same conditions by using fluorescein-labeled HSA. The reference
method gave a protein content for this support that was equal to 20.1 (± 1.1) mg/g of silica.
This value was statistically equivalent to the values that were estimated in Table 3.2 when
using the injected probes and their measured retention factors.
It can be observed in Tables 3.1 and 3.2 that the retention factors and calculated
protein contents gave similar trends in the results that were obtained for carbamazepine, Rwarfarin and R/S-warfarin. The use of even 12.5 mg/mL HSA in the on-column entrapment
method gave a similar protein content to what was obtained when using 100 mg/mL HSA
in the slurry entrapment method. Using a higher concentration of HSA in the on-column
entrapment method tended to give an increase in the measured retention factors and
estimated protein content of the final column. The column that was made using 100 mg/mL
HSA for on-column entrapment gave the highest overall retention and protein content. The
protein content of this column was about six-fold higher than the protein content that was
obtained by the slurry entrapment method when using the same concentration of HSA for
entrapment. Approximately the same increase was seen in going from the use of 12.5 to
100 mg/mL HSA for on-column entrapment.
Although the three types of probe compounds gave good agreement in the protein
contents that they provided for these columns, there were advantages and disadvantages to
the use of each type of probe. The analysis time for the elution of carbamazepine was
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shorter than for warfarin because the affinity of this drug for HSA was also weaker. This
made this probe useful for obtaining a fast estimate of the protein content; however, this
feature also made this probe more difficult to use than warfarin for examining the protein
content of small columns. R-Warfarin gave sharper elution profiles than racemic warfarin,
since this peak was due to only a single enantiomer rather than the result of two overlapping
peaks for two enantiomers. However, R-warfarin was also much more expensive than
racemic warfarin and more difficult to obtain.

3.3.3. Column stability and comparison with previous HSA columns
Table 3.3 compares the retention factors that were measured in this study for
warfarin on the columns that were prepared by entrapment vs. results obtained with
previous HSA columns that have been used with this probe and that have been prepared by
covalent immobilization methods. It can be seen that the retention factors obtained by the
entrapment method were similar to or higher than the highest retention factors that have
been obtained in prior work with HSA that has been covalently immobilized to silica by
the Schiff base method. This difference was particularly true in the case where the retention
factors were compared for the on-column entrapment method that used up to 100 mg/mL
HSA for entrapment.
The data in Table 3.3 for the entrapment method also provide some information on
the stability and reproducibility of the columns that were prepared by this approach. For
instance, the two top entries in Table 3.3 provide the range of retention factors that were
obtained over the course of about one and a half years for columns that were made by the
slurry entrapment method and the on-column entrapment method. These results indicate
that both entrapment methods were able to provide HSA supports that had good activity
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for extended periods of time when used under the storage and application conditions that
were employed in this study. These two types of columns were each stored at 4 °C when
not in use and were used for multiple injections of various probes, with typical lifetimes of
over 150 h of use at a flow rate of 0.5 mL/min.
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Table 3.3. Comparison of retention factors measured for warfarin with columns
containing immobilized HSA that were prepared by entrapment or through covalent
immobilization

Experiment/
Type of warfarin

Retention
factor, k

Method and conditions [Refs.]
Slurry entrapment method using 100 mg/mL HSA and
porous silica. Column size: 1 cm × 2.1 mm. Mobile phase:

1) Racemic

38-511

pH 7.4, 0.067 M potassium phosphate buffer.
Temperature: 37 °C.
On-column entrapment method using 50 mg/mL of HSA
and porous silica. Column size: 1 cm × 2.1 mm. Mobile

2) Racemic

70-82

2

phase: pH 7.4, 0.067 M potassium phosphate buffer.
Temperature: 37 °C

3) R-Warfarin

74 (± 4)3

Same conditions as the previous experiment
100 mg/mL of HSA, the other conditions were the same

2

4) Racemic

191-236

5) R-Warfarin

196-2242

as the previous experiment
Same conditions as the previous experiment
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Table 3.3. (Continued)
Experiment/
Type of warfarin

Retention
factor, k

R-Warfarin

2.3 (± 0.2)

S-Warfarin

98 (± 1)

Method and conditions [Refs.]
Schiff base method. Column size: 5 cm × 2.1 mm. Mobile
phase: pH 7.4, 0.067 M potassium phosphate buffer.
Room temperature [15]
Schiff base method. Column size: 5 cm × 2.1 or 4.6 mm.

R-Warfarin

394

Mobile phase: pH 7.4, 0.067 M potassium phosphate
buffer. Temperature: 37 ° C [16]

R-Warfarin

12.8 (± 0.3)5

Schiff base method. Column size: 5 cm × 4.6 mm. Mobile
phase: pH 7.4, 0.067 M potassium phosphate buffer,

S-Warfarin

26.8 (± 0.4)5

containing 5% 2-propanol and 1 mM octanoic acid.
Temperature: 25 °C [31]

R-Warfarin

82 (± 4)6

Schiff base method. Column size: 2.0, 0.5 or 0.1 cm

57 (± 6)6

length, respectively, 2.1 mm I.D. Mobile phase: pH 7.4,
0.067 M potassium phosphate buffer. Temperature: 37 °C

38 (± 8)6

[31]

1This

range of results was obtained over 1.5 years using the same column.

2This

range of results was obtained over 1.5 years from two columns.

3

These results were obtained over three injections on the same day and on one column.

4The

value was calculated from a point in a graph, so no standard error is available.

52-Propanol

and octanoic acid were used in this case as mobile phase modifiers or

competing agents to adjust and lower the retention factors for the injected analytes.
6These

are average retention factors at flow rates from 0.1 to 5 mL/min.

experiments were performed at 0.5 mL/min.

All other
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3.4.

CONCLUSIONS
Several factors were examined for maximizing the amount of HSA or Con A that

could be immobilized within porous silica by the on-column entrapment method. These
factors included the use of one or two syringe pumps, the flow rate that was used for the
entrapment process, and the protein concentration that was employed. A technique for
determining the protein content of HSA supports that were made by the on-column
approach was also developed, which was based on the use of injected probes such as
warfarin and carbamazepine. It was found in the use of on-column entrapment for HSA
that the final protein content could be increased by at least six-fold versus what has been
observed for columns that were made with the slurry method of entrapment.

The

entrapment of Con A also increased by almost three-fold with the use of the on-column
method.
One reason for the higher levels of protein that were obtained in the on-column
method is the reduced volume of the reaction slurry that was occupied by the packed
support. In the on-column method, only the void volume of the column was available for
the entrapment reaction, which probably led to an increased chance for the protein getting
entrapped when the oxidized glycogen molecules reacted with hydrazide groups on the
support. The use of flow to pass these reagents through the support may also have
increased the contact of the protein with the pores during this process.
This on-column entrapment approach can be adapted for use with other proteins or
supports. The protein content that can be obtained by this method should be advantageous
in future work with microcolumns or microfluidic systems or for any application of HPAC
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in which relative strong binding or good retention is needed in small devices or
miniaturized systems.
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CHAPTER 4.
RAPID ANALYSIS OF DRUG PROTEIN BINDING BASED ON
COLUMNS PREPARED BY ENTRAPMENT

4.1.

INTRODUCTION
It is important to know the activity and fate of pharmaceutical agents in the body.

When a drug enters the circulatory system, it may undergo interactions with proteins that
are found in blood, such as human serum albumin (HSA), α1-acid glycoprotein (AGP) and
lipoproteins. These interactions can be described by using a parameter such as the
association equilibrium constant (Ka) of the drug-protein complex. These drug-protein
interactions are often strong and significant, with approximately 43% of the 1500 most
common drugs having at least 90% binding to serum proteins.

As a result, these

interactions can have a large impact on the absorption, distribution, metabolism and
excretion (ADME) of a drug in the human body [1].
Because of the potential impact of these interactions, it is important to conduct
drug-protein binding studies on pharmaceutical agents to help determine their dosages and
the frequency at which these drugs should be taken [2]. Binding studies that are conducted
in vitro may give general information for a particular drug and its interactions, while in
vivo studies can potentially provide specific information that is more tailored to an
individual patient’s needs, as can be used for personalized medicine [3].
Human serum albumin (HSA) is a transport protein in the circulatory system that
can bind to many endogenous and exogenous compounds. HSA is the most abundant
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protein in human plasma, where it is found at concentrations ranging from 30–50 g/L
(0.53–0.75 mM). The high concentration of HSA accounts for approximately 60% of the
total protein content in serum and gives this protein the ability to greatly influence the
pharmacokinetics and activity of many common drugs [4-6]. HSA plays a key role in the
reversible binding and transport of drugs, metabolites, and various endogenous ligands
such as fatty acids. In addition, HSA can increase the solubility of lipophilic drugs,
sequester toxins, and act as an important antioxidant in plasma [7,8].
There are two major binding sites for drugs on HSA, which are located in
subdomains IIA and IIIA of this protein. These sites are often referred to as Sudlow sites
I and II after Gillian Sudlow, who proposed their existence in 1975 [9,10]. Sudlow site I,
which is also known as the warfarin-azapropazone site, binds to bulky heterocyclic anions
such as warfarin and salicylate. Sudlow site II, or the indole-benzodiazepine site, binds
primarily to aromatic carboxylic acids like ibuprofen and L-tryptophan. At least two minor
binding sites for drugs HSA have also been proposed for compounds such as digitoxin and
tamoxifen (i.e., the digitoxin site and tamoxifen site) [11,12].
Diabetes is a metabolic disease that can be described as a group of disorders that
result from insulin deficiency and/or insulin resistance. Insulin is a hormone produced in
the beta cells of the islets of Langerhans of the pancreas and is responsible for the regulation
of glucose in the circulation. The presence of either insulin deficiency or insulin resistance
in diabetes produces abnormally high levels of glucose in blood and results in a condition
known as hyperglycemia [13,14]. Diabetes is a major cause of morbidity and mortality,
and its global prevalence is growing rapidly [15]. The number of people worldwide who
have diabetes is estimated to be around 366 million, and this figure is projected to rise to
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552 million by 2030. In the United States, it is estimated that 26 million people now live
with this disease [3,16]. The high blood glucose concentrations that are seen in diabetes
can lead to a number of detrimental health effects, ranging from an increased risk of heart
disease and stroke to kidney disease, blindness, and lower limb amputations [13].
There are two types of diabetes: type 1 diabetes, which is also known as immunemediated, insulin-dependent or juvenile-onset diabetes; and type 2 diabetes, which is also
called non-insulin dependent or adult-onset diabetes. In type 1 diabetes, the body’s
immune system attacks the pancreatic beta cells that produce insulin. Type 2 diabetes is
caused by an inadequate cellular response to insulin in organs or tissue (e.g., adipose cells).
This later type of diabetes is the most common, accounting for 90 to 95% of the individuals
with this disease, and is strongly related to obesity, age, and a family history of this disease
[3,16].
Many of the long term complications of diabetes, such as heart disease and nerve
damage, are associated with the non-enzymatic glycation of proteins that occurs in the
presence of sustained high levels of glucose in blood [14,17]. The process of protein
glycation is shown in Figure 4.1. Glycation starts when a reducing sugar such as glucose
undergoes a nucleophilic attack onto a primary amine group on a protein to form a
reversible Schiff base. This intermediate can then slowly rearrange to form a more stable
Amadori product [14,17,18]. Oxidation and rearrangement of the Amadori products or
free sugars can also generate reactive α-oxaloaldehydes that react with both lysines and
arginines on proteins to form advanced glycation end-products (AGEs) [14,18].
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Figure 4.1

General reactions involved in the glycation of a protein such as human serum
albumin (HSA). This figure is adapted with permission from Ref. [14].
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In recent years, it has been found that the glycation of HSA may affect its binding
to solutes such as many drugs. Sulfonylureas, which are often used to treat type 2 diabetes,
are one group of drugs that have been found to be affected by this glycation process. These
drugs are highly bound to serum proteins, and especially to HSA [14,19-24]. Binding
studies based on high-performance affinity chromatography (HPAC) have found that
glycation can affect the equilibrium constants of sulfonylurea drugs with HSA and that the
extent of this change is affected by both the degree of protein glycation and the specific
drug that is being examined [3,14,19-23,25].
This chapter deals with the application of a new and rapid approach for performing
drug-protein binding studies by using preparations of entrapped proteins and zonal elution
experiments. The use of columns that contained entrapped proteins should allow the
determination of binding constants from simple retention measurements because the
immobilized protein in such a column remains in a soluble state and is fully active. This
feature should allow for a simplification in the measurements that are needed for
determining binding constants through chromatographic methods, because there is no need
to perform additional independent experiments to obtain the amount of active ligand that
is present in the column [19].
This technique will be tested and applied to studying the effects of glycation on
HSA with regards to the binding of this protein with three sulfonylurea drugs:
acetohexamide, tolbutamide and gliclazide. The results will be used to see how HPAC and
columns made by entrapment can be used to study the effects of glycation on drug-protein
binding and to determine the binding constants of a drug with a protein through a simple
set of experiments and series of sample injections.

109

4.2.

EXPERIMENTAL SECTION

4.2.1. Materials
The HSA (essentially fatty acid free, purity ≥ 96%), glycogen (bovine liver, type
IX; total glucose ≥ 85%, dry basis), racemic warfarin (purity ≥ 98%), R-warfarin (purity ≥
97%), L-tryptophan (purity ≥ 98%) and periodic acid reagent (H5IO6, purity 99%) were
purchased from Sigma-Aldrich (St. Louis, MO, USA). Nucleosil Si-300 silica (7 m
particle diameter, 300 Å pore size, 100 m2/g surface area) was obtained from MachereyNagel (Düren, Germany). The in vitro samples of glycated HSA were purified through the
use of Econo-Pac 10DG desalting columns from Bio-Rad Laboratories (Hercules, CA,
USA) and Slide-A-Lyzer digest 7K dialysis cassettes (7 kDa MW cutoff; 0.5-3, 3-12 or 1230 mL sample volumes) from ThermoScientific (Rockford, IL, USA). All other chemicals
were of the purest grades available. All buffers and aqueous solutions were prepared using
water from a Milli-Q Advantage 10 system (EMD Millipore Corporation, Billerica, MA,
USA). The buffers were filtered through 0.20 μm GNWP nylon membranes from Millipore
(Billerica, MA, USA) and were degassed by sonication under vacuum for at least 20 min
prior to use. A fructosamine assay kit, obtained from Diazyme Laboratories (San Diego,
CA, USA), was used to measure the glycation levels of the in vitro glycated HSA.

4.2.2. Apparatus
The chromatographic system that was used in the zonal elution studies consisted of
a DG-2080 degasser, two PU-2080 pumps, an AS-2057 autosampler, a CO-2060 column
oven, and a UV-2075 absorbance detector from Jasco (Tokyo, Japan), plus a Rheodyne
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LabPro six-port valve (Cotati, CA, USA). LC Net and ChromNav from Jasco (Tokyo,
Japan) were used to control the chromatographic system and to collect the data.
For the frontal analysis studies, two 1200 isocratic pumps and a 1200 autosampler
from Agilent (Santa Clara, CA, USA) were used, along with a Series 200 UV-Vis detector
and a vacuum degasser from Perkin Elmer (Waltham, MA, USA). A Rheodyne LabPro
valve and an Isotemp 9100 circulating water bath (Fisher Scientific, Pittsburgh, PA, USA)
with a water jacket from Alltech (Deerfield, IL, USA) were used for temperature control
of the columns. The chromatographic data in this case were collected and processed using
LabView 8 software (National Instruments, Austin, TX, USA).
The results for the zonal elution and frontal analysis experiments were analyzed by
using PeakFit 4.12 (Systat Software, San Jose, CA, USA). Regression analysis of the
frontal analysis data was performed with Origin 2015 (OriginLab, Northampton, MA,
USA). The calculation of retention factors and binding constants was performed with
Microsoft Excel 2013 (Microsoft, Redmond, WA, USA).
A Pack-in-a-Box system (ChromTech, Apple Valley, MN, USA) was used for
packing the supports into the columns.

Two PHD Ultra syringe pumps (Harvard

Apparatus, Holliston, MA, USA) were used for the on-column entrapment method. A
Jasco V-630 UV/VIS spectrophotometer (Jasco, Kyoto, Japan) equipped with temperature
control for the cuvette holder was used for taking absorbance readings during the
fructosamine assay.
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4.2.3. Preparation of in vitro glycated HSA
Three samples of in vitro glycated HSA were prepared at physiological
concentrations of HSA and glucose, as described previously [26-28]. These samples were
representative of glycation levels that are found in patients with prediabetes, confirmed
diabetes, and advanced diabetes, and will be referred to in this chapter as “gHSA1”,
“gHSA2” and “gHSA3”, respectively. To prevent bacterial growth during the glycation
process, all materials (e.g., glassware and spatulas) were first sterilized in an autoclave. A
pH 7.4, 0.20 M potassium phosphate buffer containing 1 mM sodium azide was prepared
for use in this procedure. This buffer was also sterilized in an autoclave to prevent bacterial
growth.
The in vitro glycated HSA was prepared by dissolving 840 mg of normal HSA into
a solution that contained 5 mM, 15 mM or 30 mM glucose (i.e., for the preparation of
gHSA1, gHSA2 or gHSA3, respectively) in sterile pH 7.4, 0.20 M phosphate buffer. The
final concentration of HSA in these solutions was 42 mg/mL, or 0.63 mM.

This

concentration of HSA was within the typical range (35–50 g/L) that is found in human
serum under normal physiological conditions.

These protein/glucose mixtures were

incubated for five weeks at 37 °C to produce glycated HSA. The proteins in these samples
were later purified through the use of size exclusion columns and pH 7.4, 0.067 M
potassium phosphate buffer to remove the excess glucose. The collected protein fractions
were further dialyzed three times, using sterile dialysis cassettes and against a volume of
water that was 200-500 times the volume of the protein solution [26]. The final protein
solutions were lyophilized and stored at -80 °C until further use.
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Portions of the in vitro glycated HSA samples were analyzed in triplicate by using
a fructosamine assay to determine their glycation levels, as described previously
[26,29,30]. The measured glycation levels were 0.27 (± 0.01), 2.01 (± 0.05) and 4.13 (±
0.08) mol hexose/mol HSA for gHSA1, gHSA2 and gHSA3, respectively. These levels of
glycation were comparable to those obtained in prior studies that used a similar approach
to prepare in vitro glycated HSA [26,30].

4.2.4. Support preparation
Diol-bonded silica was prepared from Nucleosil 300-7 silica, as described
previously, followed by the drying of this support and its storage for future use. Hydrazideactivated silica was prepared from the diol-bonded silica also according to a procedure that
has been described in the literature [31]. The support size of 7 µm and the pore size of 300
Å that were chosen for these supports have previously been found to be optimal for the
entrapment of HSA and proteins with comparable sizes [32].
An amount of hydrazide-activated silica that was equivalent to an initial amount of
50 mg of diol-bonded silica was washed with pH 7.4, 0.067 M potassium phosphate buffer
and downward slurry packed into 1.0 cm × 2.1 mm stainless steel columns by using pH
7.4, 0.067 M potassium phosphate buffer as the packing solution, as indicated in Section
3.2.3 of this dissertation. The columns that were packed with the hydrazide-activated silica
were used for the on-column entrapment of normal HSA or HSA with various levels of
glycation.
The conditions used for on-column entrapment were the same as the final
conditions of on-column entrapment that were described in Section 3.3.1 of this
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dissertation. A solution containing 50 mg/mL of the normal HSA or glycated HSA in pH
5.0, 0.10 M potassium phosphate buffer was circulated through the column at 20 µL/min
for 4 h. This was followed by the application of a solution over 16 h that contained a
mixture of the normal HSA or glycated HSA at 50 mg/mL and oxidized glycogen at 4.2
mg/mL in the same phosphate buffer. Finally, 200 µL of 1 mg/mL of oxalic dihydrazide
in the same buffer was added to the reaction mixture, and the circulation of this solution
through the column was continued for two more hours. A control column was made under
the same conditions but with the solutions of HSA being replaced with an equal volume of
pH 5.0, 0.10 M potassium phosphate buffer. All of the columns were washed by flowing
pH 7.4, 0.067 M potassium phosphate buffer through them at 0.5 mL/min for 1 h or until
a stable baseline response was reached for these columns.

4.2.5. Chromatographic studies
Stock solutions of the sulfonylurea drugs (i.e., acetohexamide, tolbutamide and
gliclazide) were prepared in pH 7.4, 0.067 M potassium phosphate buffer at a typical
concentration of 100 µM. The stock solutions of the site-specific probes were also prepared
in this buffer and had typical concentrations of 100 µM for warfarin and 1.3 mM for Ltryptophan. The acetohexamide, tolbutamide and gliclazide solutions were used within
one week of preparation. The warfarin solutions were used within one week, and Ltryptophan solutions were used within two days of preparation. It has been demonstrated
in previous studies that similar solutions of these drugs and solutes are stable over for these
given periods of time.
The mobile phases that were used in the competition studies with the site-specific
probes were prepared at concentrations that were typically 1 mM for L-tryptophan and 40
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µM for warfarin, as made by diluting the stock solutions for these probes with pH 7.4,
0.067 M potassium phosphate buffer. The injected samples for these experiments were
prepared by using the stock solutions for the sulfonylurea drugs, warfarin or L-tryptophan
and the pH 7.4, 0.067 M potassium phosphate buffer.

The concentrations of the

sulfonylurea drugs ranged from 20 µM to 40 µM. Additional experiments were performed
by using 10 µM L-tryptophan or 20 µM warfarin in the same pH 7.4 buffer, as used for
determining the retention factors and protein content of the normal HSA and glycated HSA
columns. It has been shown in previous work that the sample concentrations that were
used in this study provide linear elution conditions for the given drugs on HSA columns.
The chromatographic experiments were carried out at a typical flow rate of 0.50 mL/min
and at a temperature of 37 °C. All of the injected solutions and mobile phases that were
used in the experiments were passed through 0.2 μm filters and degassed for 10-15 min
prior to use.
In the frontal analysis experiments with warfarin and L-tryptophan, the columns
were first equilibrated with pH 7.4, 0.067 M potassium phosphate buffer. Using a six-port
valve, a switch was made from this pH 7.4 buffer to a solution containing a known
concentration of the desired probe compound in the same buffer. After a breakthrough
curve had been formed and a stable plateau had been reached, a switch was made back to
pH 7.4, 0.067 M potassium phosphate buffer to elute the retained drug or solute. These
frontal analysis experiments were carried out by using seven solutions that contained 1-40
μM warfarin, with the elution of warfarin being monitored at 307 nm, and seven solutions
containing 1-1000 μM of L-tryptophan, with elution of L-tryptophan being monitored at
280 nm. All these experiments were performed in triplicate or quadruplicate. The
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midpoint of each breakthrough curve was determined with Peak Fit 4.12 by using the
centroid of the first derivative for the curve, following smoothing by the Savitsky-Golay
method [33]. A correction for the system void time and for non-specific binding was made
by subtracting the results for the control column from the results that were obtained on
each entrapped protein column, using an approach described in previous studies [20,22].

4.3. THEORY
4.3.1. Zonal elution
The global affinity of a target compound for a binding agent with several
independent sites (e.g., as often occurs for the binding of drugs with HSA) can be described
as the addition of the affinities for all the sites on the binding agent. For a column that is
made by entrapment, essentially all the binding agent will be active and the overall
retention factor (k) of a drug or solute due to binding at these sites can be described by the
relationship in Equation 4.1 [19],
𝑘 = (𝑛1 𝐾𝑎1 + 𝑛2 𝐾𝑎2 + ⋯ 𝑛𝑛 𝐾𝑎𝑛 )𝑚𝐿𝑡𝑜𝑡 /𝑉𝑚

(4.1)

where ni is the relative moles of binding site i for a given drug or solute per mole of protein,
Kai is the association equilibrium constant for the same site and drug/solute, mLtot is the total
moles of all binding sites for the solute in the column, and Vm is the column void volume.
The global affinity in this equation is the term in parentheses and can also be represented
by the sum of these terms, nKa’. This is a number-weighted sum of the equilibrium
constants for all the binding sites for the drug or solute on the immobilized binding agent
[19].
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When a probe interacts with a single type of site on an entrapped binding agent,
Equation 4.1 can be reduced to the following expression,
𝑘 = 𝐾𝑎

𝑚𝐿𝑡𝑜𝑡
𝑉𝑚

(4.2)

where Ka is the association equilibrium constant for the probe with the specific binding site
[19].
Equations 4.1 and 4.2 indicate that the measured retention factor for a solute on a
column that contains an entrapped binding agent can allow a direct determination of the
global binding constant or site-specific binding constant for this solute. This can be
accomplished by using experiments like those shown in Figure 4.2. First, an injection of a
drug or solute that is dissolved in the buffer alone can be made onto a column containing
the entrapped binding agent, making it possible to determine the total retention factor, ktot.
This parameter, along with a previous measurement of the column void volume and mLtot,
makes it possible to obtain the global affinity, as is shown in the following reduced form
of Equation 4.1 [19],
𝑘𝑡𝑜𝑡 =
where 𝑛𝐾𝑎′ = ∑(𝑛𝑖 𝐾𝑎𝑖 ).

𝑛𝐾𝑎′ 𝑚𝐿𝑡𝑜𝑡
𝑉𝑚

(4.3)
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Figure 4.2

Use of zonal elution experiments for estimating the global affinity (nKa’) or
site-selective affinity (Ka1) for a solute on a column that contains an entrapped
protein or binding agent. Other terms in this figure are described in the text.
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The same drug or solute can then be injected in the presence of a mobile phase that
contains a site-selective probe (e.g., warfarin for Sudlow site I or L-tryptophan for Sudlow
site II of HSA). The agent added to the mobile phase is present at a level that saturates a
known fraction of the given site in the column. During this second injection, the retention
for the solute will be lower because the probe in the mobile phase is binding to one of the
sites on the entrapped agent. The shift in retention can make it possible to find the
association equilibrium constant for this specific binding site (Ka1), as is indicated in
Equation 4.4.
𝑘=

(𝑛𝐾𝑎′ −𝐾𝑎1)𝑚𝐿𝑡𝑜𝑡

(4.4)

𝑉𝑚

The value of mLtot in Equations 4.3 and 4.4 can be obtained through independent
frontal analysis measurements or by making a retention factor measurement with a probe
that has a known value for its association equilibrium constant with the same binding agent.
Repeating the experiment in Figure 4.2 with probes for other binding sites should make it
possible to also find the solute’s affinity for each of the other binding regions [19].
The following equations are used to obtain the experimental values of the retention
factors that are used to estimate the overall and site-specific affinities.
𝑘𝑡𝑜𝑡 =

𝑡𝑟𝑡 −𝑡𝑚
𝑡𝑚 −𝑡𝑣

𝑡 −𝑡

𝑘 = 𝑡𝑟 −𝑡𝑚

(4.5)

𝑚

𝑡 −𝑡

𝑘1 = 𝑘𝑡𝑜𝑡 − 𝑘 = 𝑡𝑟𝑡−𝑡𝑟
𝑚

𝑣

𝑣

(4.6)

(4.7)

where trt and tr are the retention times for the injected solute in the presence of only buffer
or the buffer plus the site-specific probe; and tm and tv are the void times of the column and
the system (e.g., as obtained for a non-retained solute with or without a column being
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placed in the system); and other terms are the same as defined previously. Substituting the
relationship for k1 that is given in Equation 4.7 and placing this into Equation 4.2 to solve
for Ka1 gives the following combined expression.
𝑘 𝑉𝑚

𝐾𝑎1 = 𝑚 1

𝐿𝑡𝑜𝑡𝑎𝑙

(𝑡 −𝑡 ) 𝑉

= (𝑡𝑟𝑡−𝑡𝑟) 𝑚 𝑚
𝑚

𝑣

𝐿𝑡𝑜𝑡

(4.8)

This equation shows how a site-specific binding constant for a drug with a binding
agent can be obtained from retention time measurements that are performed on both a
column that contains the entrapped binding agent and a control column.
The concentration of a site-specific probe (e.g., warfarin and L-tryptophan for
HSA) that is needed in the mobile phase to obtain a given level of saturation for the
entrapped binding agent can be found by using the following relationship,
𝑘−𝑘𝑚𝑖𝑛
𝑘𝑚𝑎𝑥 −𝑘𝑚𝑖𝑛

1

= 1+𝐾

𝐼

[𝐼]

(4.9)

where I represents the probe, KI is the association equilibrium constant for this probe at its
binding site, and [I] is the concentration of the probe in the mobile phase [33]. The terms
k, kmin and kmax are the retention factor that should result for the injected solute at a given
concentration of the probe, the minimum possible retention factor for this solute (i.e., when
all the given binding sites are saturated), and the maximum possible retention factor for the
solute (i.e., when all these sites are available for binding).
The ratio on the left of Equation 4.9 represents the relative retention that is observed
for the solute in the presence of the competing agent. This ratio is also related to the
fraction of binding sites that are available to interact with the solute. When the value of [I]
is 0, the value of k will be equal to kmax and the ratio on the left of Equation 4.9 will be
equal to 1.0 (or 0% site saturation). As the value of [I] approaches infinity, the value of k
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approaches kmin and the fraction on the left of Equation 4.9 approaches 0 (or 100% site
saturation) [33]. It is also possible to use intermediate concentrations of the competing
agent to produce a given shift in retention. For instance, the concentration of the competing
agent that is needed to reach 90% saturation at the given site on the binding agent can be
found by setting the left side of Equation 4.9 equal to 0.1 and using the remaining terms to
find the value of [I] that is needed to obtain this condition.

4.3.2. Frontal analysis
For a column with a single type of binding site for an analyte (A), Equation 4.10
describes the relationship between the apparent moles of the applied analyte (mLapp) that
are required to reach the mean position of the breakthrough curve [33].
𝑚𝐿𝑎𝑝𝑝 =

𝑚𝐿𝑡𝑜𝑡 𝐾𝑎 [𝐴]
(1+𝐾𝑎 [𝐴])

(4.10)

In this equation, mLtot is the total moles of active binding sites for the analyte in the
column, and Ka is the association equilibrium constant for the analyte at these binding sites.
This equation can be rearranged into the following form, which is useful for obtaining the
moles of active binding sites through the use of a double-reciprocal plot of 1/mLapp vs 1/[A].
1
𝑚𝐿𝑎𝑝𝑝

=𝐾

1

𝑎 𝑚𝐿𝑡𝑜𝑡 [𝐴]

+𝑚

1

𝐿𝑡𝑜𝑡

(4.11)

The frontal analysis experiments involve applying analyte solutions of various
concentrations to the entrapped protein columns, and measuring the values of mLapp that
were needed to reach the central point of each breakthrough curve. Then, using equation
4.11, it is possible to find the total moles of binding sites for A in the column, mLtot. The
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value of the association equilibrium constant Ka can be obtained from the same plot, by
using the ratio of the intercept over the slope for the best-fit line [33].
The range of analyte concentrations to be used in a frontal analysis experiment in
order to cover the range of signal variation, is calculated by employing a modified version
of Equation 4.10 [33],
𝑚𝐿𝑎𝑝𝑝
𝑚𝐿𝑡𝑜𝑡

𝐾 [𝐴]
𝑎 [𝐴])

𝑎
= (1+𝐾

(4.12)

where all the terms are the same as defined earlier. The left side of this equation is
the fraction of the binding sites in the column that are bound to the analyte at a given
concentration. The fraction is equal to zero when no analyte is applied, and approaches
one when the analyte concentration goes to infinity. For achieving measurable shifts in the
central point of the breakthrough curve, it is advisable to choose concentrations for A that
will produce a degree of saturation for the column that is between 10% and 90%, or
conditions that will give a value for the ratio on the left-hand side of Equation 4.12 that is
between 0.10 and 0.90 [33].

4.4. RESULTS AND DISCUSSION
4.4.1. Estimation of the amount of an entrapped protein in a column
The amount of HSA that was entrapped in a column was determined by using both
frontal analysis and zonal elution experiments with warfarin and L-tryptophan. The frontal
analysis experiments were carried out by using a 1.0 cm × 2.1 mm i.d. column that
contained the entrapped HSA. The application of either warfarin or L-tryptophan to this
column gave frontal analysis results that provided a good fit to Equation 4.11 and a single-
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site binding model. Figure 4.3 shows some examples of breakthrough curves that were
obtained in the frontal analysis experiments with L-tryptophan. Figures 4.4 and 4.5 show
the double-reciprocal plots that were obtained for warfarin and L-tryptophan, respectively,
when their data were analyzed according to Equation 4.11. The concentrations of the
analyte solutions that were used in these frontal analysis experiments were selected to
provide between 10% and 90% saturation of the total binding sites, as calculated by using
Equation 4.12.
The total moles of protein were also estimated by using zonal elution experiments
that were carried out with the same column and using the same analyte or probes as were
used in the frontal analysis experiments. The values for the moles of entrapped protein that
were obtained by both of these methods are provided in Table 4.1. There was good
agreement between the two methods, with no significant difference being present at the
95% confidence level. This indicated that it was possible to measure the total moles of
binding sites and protein by either method, with the zonal elution technique being preferred
in later studies because it required much less time and reagents than the frontal analysis
experiments.
The value of Ka that was obtained from the double-reciprocal plot for warfarin was
2.6 (± 0.3) × 105 M-1, which was in good agreement with an average value of 2.4 (± 0.4)
× 105 M-1 that has been previously determined for the R- and S-enantiomers of warfarin
with HSA. The value of Ka that was obtained from the double-reciprocal plot for Ltryptophan was 0.93 (± 0.23) × 104 M-1, which was also in good agreement with a value
of 1.1 (± 0.3) × 104 M-1 that has been reported in previous studies with HSA [26,33].
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Figure 4.3

Frontal analysis experiments conducted with L-tryptophan being applied to a
1.0 cm × 2.1 mm i.d. column that contained entrapped HSA. The temperature
of this column was 37 °C and the flow rate was 0.5 mL/min.
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Figure 4.4

Double-reciprocal plot obtained for frontal analysis studies with warfarin on
a 1.0 cm × 2.1 mm i.d. column containing entrapped HSA, as measured at 37
°C and 0.5 mL/min. The best-fit line was obtained by applying Equation 4.11
to these data. The inset shows the residual plot for the distribution of the data
about the best-fit line.

Figure 4.5

Double-reciprocal plot obtained for frontal analysis studies with Ltryptophan on a 1.0 cm × 2.1 mm i.d. column containing entrapped HSA, as
measured at 37 °C and 0.5 mL/min. The best-fit line was obtained by
applying Equation 4.11 to these data. The inset shows the residual plot for
the distribution of the data about the best-fit line.

Table 4.1.

Estimates of the amount of entrapped normal HSA, as determined by zonal
elution and frontal analysis

Probe or
analyte

Warfarin
L-Tryptophan

1

Column void volume,
Vm (L × 10-5)

3.35
( ± 0.07)

Moles of entrapped protein1
(mol × 10-8)
Zonal elution

Frontal analysis

1.83 (± 0.31)

1.46 (± 0.17)

1.26 (± 0.35)

1.09 (± 0.27)

These values were measured at 37 °C in pH 7.4, 0.067 M phosphate buffer. The values in

parentheses represent a range of ± 1 S.D.

4.4.2. Estimation of global affinity constant and site-specific binding constants for
acetohexamide with entrapped normal HSA
Once the total moles of entrapped normal HSA had been determined, the global
affinity constant for acetohexamide with the entrapped HSA was determined by making
injections of acetohexamide on both the entrapped HSA column and a control column. A
second set of injections were then made for acetohexamide in the presence of a siteselective probe for HSA (e.g., warfarin for Sudlow site I or L-tryptophan for Sudlow site
II) to determine the binding constants of acetohexamide at specific sites on HSA.
Equation 4.9 was used to determine the concentrations of the site-specific probes
that were needed in these experiments to achieve near complete saturation of the binding
sites. This was done by setting the left side of Equation 4.9 equal to a relative retention of
0.05 (representing 95% site saturation) for calculating the concentration that would
produce a 95% shift in retention from its maximum possible value. The known association
equilibrium constants for HSA with warfarin and L-tryptophan (i.e., the probes that were
used as site-selective additives in this work) were also used in these calculations. The
conditions needed for 95% site saturation were estimated to occur when the mobile phase
contained 79 µM warfarin or 1.7 mM L-tryptophan. Experiments that were also done at
90% site saturation, which corresponded to the use of 40 µM warfarin or 850 µM Ltryptophan in the mobile phase.
Table 4.2 shows the association equilibrium constants that were measured by zonal
elution for acetohexamide in the presence of various amounts of the mobile phase
additives.

Table 4.2.

Site-specific association equilibrium constants measured for acetohexamide
in zonal elution experiments and using various concentrations of siteselective probes in the mobile phase

Probe1

1

Site-specific association equilibrium
constant, Ka (M-1 × 104)2

Mobile phase
concentration

Sudlow site I

Sudlow site II

Warfarin/L-tryptophan

101.6 µM/1.7 mM

10.9 (± 1.9)

6.9 (± 2.0)

Warfarin/L-tryptophan

40 µM/850 µM

9.9 (± 0.18)

6.8 (± 2.0)

Warfarin (racemate)

40 µM

8.3 (± 1.4)

N.A.

R-Warfarin

40 µM

8.9 (± 0.9)

N.A.

Warfarin was used as a probe for measuring the binding constant for Sudlow site I and L-

tryptophan was used for Sudlow site II. These probes were used in separate sample solutions for
each experiment. Physiological conditions were also used in these measurements (i.e., pH 7.4,
0.067 M potassium phosphate buffer and a column temperature of 37 °C).
2

The values in parentheses represent a range of ± 1 S.D.

One observation made was that there was no significant difference at the 95%
confidence level in the association equilibrium constants that were obtained when using
mobile phase additives that corresponded to 95% or 90% site saturation. Given the fact
that lower concentrations of these additives also resulted in a decrease in reagent costs and
a lower background signal for the detector, mobile phase concentrations of 40 µM warfarin
or 1000 µM L-tryptophan were selected for use in all subsequent zonal elution studies. The
global affinity constant that was obtained in these experiments and from the retention factor
for acetohexamide was 1.96 (± 0.33) × 105 M-1, which was in good agreement with values
of 1.2-2.0 × 105 M-1 that have been previously obtained for this drug with HSA [19-21].
The impact of using racemic warfarin versus a single warfarin enantiomer as a
mobile phase additive for probing Sudlow site I was also considered in this study.
Examples of some chromatograms that were obtained in these experiments are shown in
Figure 4.6 and the results are included in Table 4.2. The association equilibrium constants
that were obtained for acetohexamide at Sudlow site I when using either type of probe were
statistically equivalent at the 95% confidence level. From this result, it was decided that
racemic warfarin would be used as the probe for Sudlow site I in all later experiments with
other sulfonylurea drugs.

Figure 4.6

Chromatograms obtained for the injection of acetohexamide onto a column
containing entrapped HSA and in the absence or presence of R-warfarin or
racemic warfarin in the mobile phase.

4.4.3. Estimation of global affinity constants and site-specific binding constants
for sulfonylurea drugs with entrapped samples of normal or glycated HSA
The use of on-column entrapment and zonal elution was next used to examine the
global affinities and site-specific binding constants for various sulfonylurea drugs with
either normal HSA or glycated HSA. As was demonstrated previously, the total moles of
HSA in such a column could be obtained from retention measurements that were made
using a well-characterized probe for such a protein. For these experiments, warfarin was
selected as the probe for measuring mLtot because this solute has been shown in previous
studies to have no significant change in its affinity in the presence of low-to-moderate
levels of glycation for HSA [19,26].
In this section, injections of racemic warfarin were first made onto columns
containing entrapped samples of normal HSA or glycated HSA, and onto a control column,
to provide an estimate of the total protein content of each column. The same columns were
then used for the injection of samples that contained the sulfonylurea drugs acetohexamide,
tolbutamide or gliclazide. These injections were initially made in the presence of only
buffer to obtain the global affinity constants for each drug with normal HSA or the samples
of glycated HSA. The same drugs were then injected in the presence of a mobile phase
that contained a site-selective probe for HSA. To examine the binding of these drugs at
Sudlow site I, 40 µM warfarin was added to the mobile phase. To examine the binding of
these drugs at Sudlow site II, 1000 µM L-tryptophan was added. The differences in the
retention times that were seen for each drug in the presence of only buffer or in the presence
of a known concentration of a site-specific probe were then used to calculate the sitespecific association equilibrium constants for each drug at Sudlow sites I and II. The global

affinity constants and site-specific association equilibrium constants that were measured
for these drugs at Sudlow sites I and II are summarized in Tables 4.3 through 4.5.
Table 4.3 shows the global affinity constants that were measured for the
sulfonylurea drugs with normal HSA or HSA with three levels of glycation: gHSA1, which
had a modification level that was typical of that seen in prediabetes; gHSA2, which had a
modification level corresponding to controlled diabetes; and gHSA3, which corresponded
to advanced/uncontrolled diabetes. For all sulfonylurea drugs, there was an increase in the
global affinity constant when going from normal HSA to gHSA1 and a further increase
when going to gHSA2. However, the global affinity constant decreased when going to
gHSA3. The highest increase that was observed was 1.3-fold, as noted for acetohexamide
and gliclazide with the gHSA2 sample. However, none of these apparent differences were
statistically significant when the standard deviations (in parentheses) were considered. The
global affinity constants for these drugs with normal HSA were in good agreement with
those reported in previous studies: 16 (± 1) × 104 for acetohexamide, 10 (± 1) × 104 for
tolbutamide, and 5.8 (± 0.2) × 104 for gliclazide [14,19,22,24].

Table 4.3.

Global affinity constants obtained for various sulfonylurea drugs with
columns containing entrapped samples of normal HSA or HSA with various
levels of glycation
Global affinity constant (M-1 × 104)
and type of HSA1

Drug
Normal HSA
Acetohexamide

1

gHSA1

gHSA2

gHSA3

18.7 (± 3.4)

20.9 (± 3.9)

25.5 (± 4.7)

22.8 (± 4.4)

Tolbutamide

9.9 (± 1.8)

11.2 (± 2.1)

13.5 (± 2.5)

12.6 (± 2.4)

Gliclazide

4.2 (± 0.8)

5.0 (± 0.9)

6.3 (± 1.2)

5.9 (± 1.1)

These values were measured at 37 °C in pH 7.4, 0.067 M phosphate buffer. The

values in parentheses represent a range of ± 1 S.D.

Table 4.4.

Association equilibrium affinity constants obtained at Sudlow site I for
various sulfonylurea drugs with columns containing entrapped samples of
normal HSA or HSA with various levels of glycation
Association equilibrium constant (M-1 × 104)
and type of HSA1

Drug

Normal HSA

1

gHSA1

gHSA2

gHSA3

Acetohexamide

10.6 (± 2.0 )

10.9 (± 2.0)

13.4 (± 2.7)

11.3 (± 2.2)

Tolbutamide

6.7 (± 1.2)

7.2 (± 1.3)

7.9 (± 1.6)

7.0 (± 1.3)

Gliclazide

2.5 (± 0.5)

2.47 (± 0.5)

3.1 (± 0.6)

2.9 (± 0.5)

These values were corrected for the fact that only 90% site saturation was used. These

results were measured at 37 °C in pH 7.4, 0.067 M potassium phosphate buffer. The
values in parentheses represent a range of ± 1 S.D.

Table 4.5.

Association equilibrium affinity constants obtained at Sudlow site II for
various sulfonylurea drugs with columns containing entrapped samples of
normal HSA or HSA with various levels of glycation.
Association equilibrium constant (M-1 × 104)
and type of HSA1

Drug

Normal HSA

1

gHSA1

gHSA2

gHSA3

Acetohexamide

6.4 (± 1.2)

6.7 (± 1.2)

9.9 (± 2.0)

7.9 (± 1.6)

Tolbutamide

5.2 (± 0.9)

3.3 (± 0.7)

4.5 (± 0.9)

5.0 (± 0.9)

Gliclazide

1.7 (± 0.3)

2.1 (± 0.4)

3.4 (± 0.7)

3.0 (± 0.6)

These values were corrected for the fact that only 90% site saturation was used. These

results were measured at 37 °C in pH 7.4, 0.067 M potassium phosphate buffer. The
values in parentheses represent a range of ± 1 S.D.

Tables 4.4 and 4.5 compare the sulfonylurea drugs in terms of their association
equilibrium constants for the two main drug binding sites on HSA: Sudlow sites I and II.
In general, an increase in these site-specific binding site constants was observed for the
three drugs when going from normal HSA to gHSA2. The affinity then tended to decrease
with further glycation, as was typical of uncontrolled diabetes (gHSA3). The binding
constant for Sudlow site I increased by 1.3-fold for acetohexamide, 1.2-fold for
tolbutamide and 1.3-fold for gliclazide for gHSA2 relative to normal HSA. The binding
constant for Sudlow site II increased by 1.5-fold for acetohexamide and 2-fold for
gliclazide for gHSA2 relative to normal HSA. No increase was observed in the binding
constant at Sudlow site II for tolbutamide as a result of glycation.
The association equilibrium constants at Sudlow site I and II were also compared
between the various drugs. For instance, the binding constant at Sudlow site I was higher
than the value at Sudlow site II for acetohexamide in normal HSA as well as in all of the
samples of glycated HSA. The same trend was true for tolbutamide. For gliclazide, there
was no statistically significant difference between the values that were measured at Sudlow
sites I and II.

4.5. CONCLUSIONS
In this study, a novel approach was developed and tested for measuring global
affinity constants and site-specific binding constants for drug-protein interactions. This
method made use of columns containing entrapped proteins. With these columns, it was
possible to estimate drug-protein binding constants by using relatively simple retention
measurements for a drug in the presence of only a buffer or in the presence of a probe for
each specific binding site that was to be studied.
The system was applied to the sulfonylurea drugs acetohexamide, tolbutamide and
gliclazide, which are known to bind tightly to HSA and to have interactions at both Sudlow
sites I and II of this protein [14,19-24]. A sample of normal HSA and three samples of
HSA with various levels of glycation were immobilized by on-column entrapment using
the conditions that were optimized in Chapters 2 and 3 of this dissertation.
In order to calculate the binding constants for these drugs with normal HSA or
glycated HSA, it was necessary to also have an estimate of the total moles of active protein
that were in each column. This estimate was made by using both zonal elution and frontal
analysis experiments with a probe compound (i.e., warfarin) that had known interactions
with these proteins. It was found that the values obtained by zonal elution were statistically
equivalent to those measured with the more time-consuming method of frontal analysis.
Racemic warfarin was used for this type of measurement in the later work with the normal
HSA and glycated HSA, because it has been shown in previous studies that the affinity of
this drug for HSA is not affected significantly by the glycation of HSA at the modification
levels that are normally seen in diabetes [19,26].

The global affinity constants for several sulfonylurea drugs were measured by this new
approach. Good agreement was seen between these values and those that have been previously
estimated for these drugs with HSA. It was also shown how site-specific association equilibrium
constants for these drugs could be measured with either normal HSA or glycated HSA. Good
agreement was seen between the global affinity constants that were found in this study and
values that have been calculated previously for the same drugs with HSA.
The change in binding affinity of sulfonylurea drugs to HSA as a function of glycation has
profound biological implications in terms of changes in efficacy and side-effects of the diabetes
drugs. The rapid approach addressed in this chapter for studying protein-drug interactions by
using entrapped proteins in HPAC columns can be applied for screening the binding of drugs with
proteins isolated from serum of patients with some pathological condition in order to tailor the
treatment to each individual.
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CHAPTER 5.
MICROFLUIDIC DEVICES WITH ENHANCED
FLUORESCENCE DETECTION WITH MONOLITH
SUPPORTS AND SILVER NANOPARTICLES

5.1.

INTRODUCTION
The systems involved in the studies addressed in the first four chapters of this

dissertation can be classified within the normal analytical scale. However, nanotechnology
has opened up a new frontier for analytical sciences, leading to the development of
microfabricated devices. These systems can be fabricated from glass, silicon, or polymerbased materials and fulfill the requirements for the creation of a complete “laboratory-ona-chip” [1].

Affinity and immunoaffinity separation techniques are well suited to

integration into these microsystems due to the specificity and fast reaction times that can
occur in these systems for the analytes of interest. Affinity and immunoaffinity devices
can be static, such as protein arrays, or can be based on microfluidics, as can occur when
using capillary electrophoresis and chromatographic microfluidic systems [1,2].
One of the most appealing advantages of these microfluidics devices is the low
limits of detection that can be attained with them, even when they are used with very small
samples and small amounts of reagents. This is especially true when these devices are
combined with fluorescence detection or mass spectrometry. This makes microfluidic
devices attractive for use in biointeraction systems or for biomedical analysis [1,3]. The

development of nanomaterials (including carbon nanotubes, silica nanoparticles, gold or
silver nanoparticles, magnetic beads, quantum dots and multifunctional core-shell systems)
has led to approaches that may provide even greater signal intensities and higher stabilities
in these signals at low detection limits [3-5]. For example, the increased surface areas for
many of these materials can allow for an increase in sensitivity by providing more reaction
centers, with some devices using nanomaterials allowing for detection in the nM or pM
range [2,6-8].
Fluorescence-based detection has intrinsically high sensitivity due to the large
extinction coefficients and quantum yields of the fluorescent labels that are in common use
[9,10]. However, in the visible range of the electromagnetic spectrum, fluorescence
detection suffers from interferences and frequently has a high background signal that is
produced by autofluorescence and light scattering from biological components, membranes
or plastics that are used in the construction of sensors or microfabricated platforms [7].
An alternative to overcome this problem is to use near-infrared (NIR) fluorescent
labels for detection. NIR fluorescence involves the absorption and emission of light in the
range of 700–900 nm. NIR fluorescent dyes can offer better sensitivity and higher signalto-noise ratios than traditional fluorescent labels because the autofluorescence from
common biological components such as proteins and cells is greatly reduced in the NIR
region [10]. Plastics that are commonly used in detection or microfluidic systems, such as
nitrocellulose, polyvinylidene difluoride (PVDF), poly(methylmethacrylate) (PMMA),
and

polydimethylsiloxane

(PDMS),

also

have

reduced

light

scattering

and

autofluorescence in the NIR region [7]. For this reason, NIR fluorescent labels have been
of great interest for use in analyzing trace substances in biological environments [11,12].

Despite their drastic reduction in interferences and background signals, NIR
fluorophores still suffer from lower signal intensities than fluorophores in the visible range
of the spectrum, which is caused by their low intrinsic quantum yield [13]. Thus, there
remains a need for improved sensitivity for these dyes, in order to expand the use of NIR
fluorescence in the biomedical and bioanalytical fields. An approach to overcome the low
intrinsic quantum yields of these fluorophores, and to improve the signal from NIR
fluorescent probes, is to use plasmon-active nanostructures (e.g., made from gold or silver)
located near but not in direct contact with the fluorophore. The close proximity of the
nanoparticles and NIR fluorescent probe produces an effect known as surface-enhanced
fluorescence (SEF).
SEF occurs because metal nanoparticles (mNPs) have conduction band electrons.
When these free electrons are subjected to an electromagnetic field at a certain frequency,
they are forced to oscillate within the particle volume and slightly into the surrounding
material [14]. The oscillating electron clouds, which are referred to as surface plasmons,
act as energy collectors that can concentrate energy from a large volume (e.g., the volume
occupied by the light beam or laser used to illuminate a NIR fluorescent probe) to the much
smaller volume that is occupied by the nanoparticles [15]. This causes electromagnetic
fields to be greatly increased in the regions where the mNPs are concentrated and between
joints and clusters of mNPs. Consequently, the excitation and emission rates of the
fluorophore are greatly increased [16]. mNPs have been referred to as nanoantennas
because of their ability to concentrate energy from a large space into a smaller region [1720]. In areas of the material where the mNPs form clusters or junctions, known as “hotspots”, the fluorescence intensity can be dramatically improved by SEF [21-25]. By

combining NIR fluorescent dyes and SEF, it is possible to improve the limits of detection
for these dyes in fluorescence-based assays by simultaneously increasing the signal and
reducing the background noise of the signal [26,27].

5.2.

EXPERIMENTAL SECTION

5.2.1. Materials
The glycidyl methacrylate (GMA, 97% pure), ethylene dimethacrylate (EDMA,
98%), 1-dodecanol (98%) and cyclohexanol (99%) were purchased from Sigma-Aldrich
(St. Louis, MO, USA). The PDMS prepolymer and curing agent were also obtained from
Sigma-Aldrich. Camphorquinone (99%) and ethyl-4-dimethylaminobenzoate (99%) were
purchased from Alfa Aesar (Ward Hill, MA, USA). All other reagents were of the purest
grades available. A citrate-stabilized solution of silver nanoparticles (AgNPs; 18 nM with
an average particle diameter of 18 Å) was a gift from LI-COR Biosciences (Lincoln, NE,
USA). The AgNP solution was swirled and filtered through 0.20 μm nylon Acrodisc
syringe filters (Pall, Washington, NY, USA) before use to eliminate any aggregates that
may have formed in this preparation. A Vivaspin ultrafiltration spin column (300 kDa MW
cutoff; Sartorius, Götingen, Germany) was used for isolating the AgNPs from their original
solution. The IRDye 800 CW carboxylate dye was obtained from LI-COR Biosciences.
All buffers and aqueous solutions were prepared using water from a Milli-QAdvantage 10
system (EMD Millipore Corporation, Billerica, MA, USA). The buffers were filtered
through 0.20 μm GNWP nylon membranes from EMD Millipore prior to their use.

5.2.2. Solution preparation
A solution containing the IRDye 800 CW carboxylate dye was prepared by
combining the contents of a vial that contained 20 nmol of this dye with 0.5 mL of pH 7.4,
0.067 M potassium phosphate buffer. This gave a 40 µM solution of this dye that was kept
in the freezer at -20 °C. From this solution a diluted stock solution containing 1000 nM of
the same dye was prepared by dilution with pH 7.4, 0.067 M potassium phosphate buffer.
This diluted stock solution was stored at 4 °C and used within one month of preparation.
The working standards were made from the 1000 nM dye solution by diluting them with
pH 7.4, 0.067 M potassium phosphate buffer. These standards were used within two days
of their preparation. All of these solutions were protected from the light by covering their
vials with aluminum foil and storing the solutions in the dark.

5.2.3. Apparatus
Measurements of the IRDye 800 CW carboxylate dye were carried out by using the
optical components of a 4200 near-infrared (NIR) fluorescence microscope that were
provided by LI-COR. This type of microscope was equipped with 680 and 780 nm diode
laser sources that were focused into a 200 µm electron beam at a short distance from the
detection objective lens. When one of these lasers (modulated at 9.2 kHz) illuminates a
sample containing an appropriate NIR fluorescent dye, some of this dye may be excited
and its fluorescent signal is converted into an electrical signal by an avalanche photodiode
detector. The signal is preamplified in the detector and sent to a 4000M microscope
controller, which was also from LI-COR. The controller demodulates the signal and
provides a DC analog output that is proportional to the concentration of the dye in the
sample.

This optical system was mounted onto a programmable platform from National
Aperture (Salem, NH, USA) that could be moved in the x, y and z directions. This platform
allowed travel up to 138 cm in any direction, with speeds up to 7.6 mm/s at a repeatability
of 0.2 µm and with an accuracy of 0.7 µm. This combined system was used in this research
to scan samples that contained the NIR fluorescent dye, to measure this dye, and to examine
the signal of this dye as a function of position in a sample or in a device that contained the
dye’s solution (see Figure 5.1). LabView 8.0 and a data acquisition board from National
Instruments (Austin, TX, USA), along with programs written in-house, were used for
recording the signal from the NIR fluorescent microscope and for controlling the movable
platform. A PHD Ultra syringe pump (Harvard Apparatus, Holliston, MA, USA) and a 0.5
µL Rheodyne valve (Rohnert Park, CA, USA) were used for the delivery of samples and
solutions to the microfluidic devices that were placed onto the movable platform.

5.2.4. Construction of microfluidic devices
The microfluidic chips were made by employing a PDMS prepolymer and curing
agent, which were mixed at a ratio of 10:1 and degassed under vacuum for 1 h [28]. This
PDMS polymerization mixture was then cast onto a master mold made of polyethylene
through 3D printing and containing the desired form of the microchannel (e.g., 2.5 cm
length × 200 µm width × 50 µm depth). Next, the PDMS was thermally cured at 60 °C for
1 h. This combination of time and temperature was determined in this study to produce a
stiff PDMS slab that still had enough elasticity to allow for cutting. The slab was then
gently peeled off of the mold, to avoid damaging the microchannel, and the excess material
was cut away [28,29]. The PDMS surface with the microchannel and a glass slide were
treated separately with an oxygen plasma for 30 s. Immediately after this plasma treatment,

the PDMS and glass slide surfaces were aligned onto each other. This combined device
was then placed into an oven at 80 °C for 15 min to finalize the bonding of the PDMS to
the glass slide [29,30]. The inlet and outlet of the resulting device were punched by using
a 0.048 inch o.d. biopsy tool, and type PE-60 polyethylene tubing (0.048 inch o.d., 0.036
inch i.d.) was inserted into the device after the holes had been made with the biopsy tool
[31].

5.2.5. Monolith preparation
Monoliths based on poly(glycidyl methacrylate-co-ethylene dimethacrylate)
(GMA/EDMA) were prepared by photopolymerization [32]. This was begun by mixing
all of the components shown in Table 5.1 except for the photoinitiators (i.e.,
camphorquinone and ethyl-4-dimethylaminobenzoate). Before these components were
mixed, the cyclohexanol and 1-dodecanol were heated in a water bath at 40 °C to get them
into the liquid state. The monomer ratio and the proportion of the porogenic solvents that
were used have been previously found to be appropriate for making monoliths that can be
used for immobilizing proteins or antibodies and for use in affinity-based columns [32,33].
All of the components in Table 5.1 were then pipeted into a vial except the photoinitiators.
The contents of this vial were placed onto a vortex mixer for 5 min in the dark. The
photoinitiators were then added and mixing was continued for another 2 min. This mixture
was poured onto a glass slide to form monolith layers or injected with a syringe into a
microfluidic device. A light source was used to irradiate this mixture with intense blue
light (472 nm) for a total 3 min, which was divided in 30 s intervals over which a different
section of the mixture was irradiated. The light source was held at a distance of 1–2 cm
from the mixture during this process. The glass slide or microfluidic chip was then placed

into an UV-curing oven, where it was exposed to blue light for 10 min to complete
photopolymerization of the monolith. The protocol produced monoliths with enough
mechanical stability for use in flow-based devices [30,33].
When curing was finished for the microfluidic devices, the tubing was taken off the
PDMS slab and new PE-60 tubing was inserted through the inlet holes. In the microfluidic
devices that were made later in this chapter, more of the PDMS polymerization mixture
was applied around the entrance points of the inlet tubes, followed by heating at 60 °C for
1 h in an oven to cure this PDMS and to provide a good seal around the tubing. These
devices were then mounted onto the microscope stage, as shown in Figures 5.1 and 5.5,
and connected with PEEK tubing to a syringe pump for the application of sample and
solutions to the system.

Figure 5.1

(Top) Microfluidics chip containing a 2.2 cm × 250 µm × 500 µm channel
filled with a GMA/EDMA monolith.

(Bottom left) An x-y-z scanning

platform that contains a mounted microfluidic chip. (Bottom right) General
components of the NIR fluorescence microscope stage. In this work, the
platform containing the microfluidic chip was located in front of the
microscope’s objective lens.

Table 5.1.

Composition of the polymerization mixture that was used with
photoinitiation to make EDMA/GMA monoliths.

Component

(% w/w)

mass (g)

Volume (mL)

GMA1

20

0.2

0.1860

EDMA1

20

0.2

0.1902

1-Dodecanol

48

0.48

0.5853

Cyclohexanol

12

0.12

0.126

Camphorquinone

0.0042

Ethyl-4-dimethylaminobenzoate

0.0042

1

Monomers: GMA, glycidyl methacrylate; EDMA, ethylene dimethacrylate.

2

These photoinitiators were added in a 1% (w/w) amount versus the monomers.

5.3.

THEORY

5.3.1. Fluorescence spectroscopy
The energy absorbed by a molecule when irradiated by light must be released to the
environment either 1) as heat through molecular vibrations and collisions or 2) as light by
the processes of fluorescence or phosphorescence, which occur on two very different
timescales. Figure 5.2 shows a Jablonski diagram [34] that illustrates the mechanisms of
fluorescence and phosphorescence. Upon the absorption of a photon with an appropriate
amount of energy, a molecule is initially excited from an electronic ground state (S 0) to its
first excited state (S1) over a short period of time (about 10-15 s) [34,35]. Over a time scale
of about 10-12 s, the molecule relaxes to the ground vibrational state of its first excited
electronic state. As the system relaxes, energy is released in the form of heat to the
environment. The molecule stays a time period of a few nanoseconds in the first excited
state, which corresponds to the fluorescence lifetime. Then, a photon is emitted in a process
that again only lasts about 10-15 s [35]. Finally, the molecule releases more vibrational
energy as heat, eventually returning to the lowest vibrational state of its ground electronic
state. Because of the two vibrational relaxation steps that occur during this process, the
emitted light will have less energy (or have a longer wavelength) than the absorbed light.
Aromatic molecules with delocalized electrons can undergo relaxation by fluorescence or
phosphorescence. These fluorophores may be from a natural source (e.g., tryptophan and
naturally fluorescent proteins such as green fluorescent protein, GFP) or they can be
synthetic in origin (e.g., Cyanine, Alexa, and Atto) [11].

Figure 5.2 General scheme showing the energy states that are associated with
fluorescence and phosphorescence. A photon with energy hν is first absorbed
by a molecule, causing an electron to move from a ground state (S 0) to an
excited singlet electronic state (S1). The molecule losses some energy as heat
as it moves to the lowest excited vibrational state in this electronic level. In
fluorescence, a photon is then emitted, allowing the electron to move back to
its ground electronic state. In phosphorescence, the excited electron instead
first passes from the singlet state (S1) to a triplet state (T1) by means of intersystem crossing. The lifetime of this T 1 state can be quite long (i.e.,1 ms to
hours). Reproduced with permission from reference [34].

Fluorescence spectroscopy is conducted by exciting a fluorescent compound with
light source at an appropriate wavelength and collecting the light that is emitted at a longer
wavelength. The excitation source can be a laser, a light-emitting diode, or a broadband
filament bulb that is equipped with a filter. The wavelength difference between the
absorption and emission maxima is known as the Stokes’ shift, and is usually 10-20 nm for
organic-based fluorescent compounds. This is illustrated in Figure 5.3 by using the
absorption and emission spectra for the NIR fluorescent dye IRDye 800CW, which was
used for the studies reported in this chapter [10,12,34,35].

5.3.2. Surface-enhanced fluorescence
Surface-enhanced fluorescence (SEF) has been known for decades but only
recently has it gained popularity within the scientific community. This technology makes
it possible to significantly improve the quantum yield for a fluorophore by increasing the
excitation rate of the fluorophore as well as improving its photostability [3]. The use of
nanoparticles to enhance optical detection started to grow more rapidly when the related
phenomenon of surface-enhanced Raman scattering (SERS) became popular in the
research community [36,37]. Raman scattering is important because every molecule has a
unique scattering spectrum. Unfortunately, Raman intensities are extremely low and, even
with an enhancement in sensitivity, detecting this type of scattering remains an issue that
limits the application of SERS in bioanalysis [36].

Figure 5.3

Absorption (red) and emission (blue) spectra for the dye IRDye 800CW in
phosphate buffered saline. Copyright LI-COR, Inc. by permission.

The fluorescence enhancement of NIR dyes has been demonstrated with gold
nanoparticles (AuNPs) and silver nanoparticles (AgNPs) in solution and on surfaces
[4,5,13,38]. Gold nanostructures [39-45] and silver nanostructures [24,36,37,45] have
been used for sensors that use light in NIR region [13], as well as in SERS detectors that
have increased sensitivity [43]. Common examples of nanostructures that are used in
fluorescence sensors with SEF are silver and gold nanoparticles. Plasmon resonance can
produce fluorescence quenching or fluorescence enhancement for organic fluorophores,
which will depend on the emission wavelength, the distance of the fluorophores to the
metal nanoparticles, and the size of the nanoparticles [6,46-48]. Quenching usually
dominates when the fluorophore is located at a short distance from the surface (i.e.,
typically within 5 Å) [44,49]. The plasmonic enhancement of fluorescence dominates
when using gold and silver at greater distances [49].
The intrinsic fluorescence yield can be represented by the following expression
[10,34],
0
0
𝛾𝑒𝑚
= 𝛾𝑒𝑥
Φ0

(5.1)

0
0
where 𝛾𝑒𝑚
and 𝛾𝑒𝑥
are the fluorescence emission rate and excitation rate, respectively.

The term Φ0 is the quantum yield, which can be expressed as the ratio of the radiative
decay rate to the total decay rate. In this case, Equation 5.1 turns into Equation 5.2
[49,50],
𝛾0

𝑟
0
0
𝛾𝑒𝑚
= 𝛾𝑒𝑥
∙ 𝛾0 +𝛾
0
𝑟

𝑛𝑟

(5.2)

0
where 𝛾𝑟0 and 𝛾𝑛𝑟
are the radiative and non-radiative intrinsic decay rates, respectively.

In the presence of surface plasmons, the excitation decay rate and the radiative
decay rate are increased to γem and γex respectively, and a new term appears for the nonradiative decay. This gives the following enhanced emission rate.
𝛾𝑟

𝛾𝑒𝑚 = 𝛾𝑒𝑥 ∙ 𝛾 +𝛾
𝑟

0
𝑛𝑟 +𝛾𝑛𝑟

(5.3)

The second term in this expression is the enhanced quantum yield, Φ. SEF can
then be described as a combination of enhanced excitation rate and quantum yield [51].
𝛾

Φ

𝑆𝐸𝐹 = 𝛾𝑒𝑥
0 ∙ Φ0
𝑒𝑥

(5.4.)

According to these equations, the fluorescence of a probe can be enhanced by
increasing the excitation rate or the quantum yield [52]. The quantum yield cannot exceed
unity, so there is a limit as to how much the fluorescence can be increased by this factor,
especially for fluorophores that already have high intrinsic quantum yields. A local
increase in field intensity can improve the excitation rate as well as the quantum yield, and
is dependent on the optical properties of the material that forms the nanostructure, the
geometry of the nanostructure, the orientation of the emitter dipole, and distance between
the emitter and the nanostructure [53].

5.4.

RESULTS AND DISCUSSION

5.4.1. Initial alignment of NIR fluorescence microscope stage
To align the stage of the scanning platform with the optics of the NIR fluorescence
microscope, a piece of graph paper was glued to a glass slide that was fixed to the

microscope stage by using double sided tape. The graph paper served as a guide for finding
the optimum distance between the objective of the microscope and the surface to be
analyzed. The microscope stage was moved in the x-y-z planes with three servo motors
that were controlled through a program written in LabView.
The initial signal adjustment was carried out by moving the platform in the z-axis
until the red laser dot from the light source reflected on the surface of the paper and was
centered in front of the objective. The final adjustment was achieved by moving the stage
small distances along the z-axis (i.e., between 1000 and 200 counts, with 1 mm equaling
2800 counts) while observing the variation in the detector’s signal until a maximum output
was achieved.
It was observed that the background signal resulting from the light that was
reflected and scattered by the paper’s surface reached a maximum when the objective was
located 13.2 mm from the paper. In the following experiments, a piece of heavyweight
paper cut with a 13 mm width was used as a guide for setting the initial distance between
the microscope objective and the surface of the sample. The final distance adjustment was
made by moving the stage along the z-axis in small increments, as described in the previous
paragraph.
Working solutions were prepared by taking a stock solution containing 1000 nM of
the IR800 CW carboxylate dye and diluting it with pH 7.4, 0.067 M potassium phosphate
buffer. The following dye concentrations were used for the initial studies in this chapter:
10 nM, 100 nM, 500 nM, and 1000 nM. Five drops of each solution were applied to
EDMA/GMA monoliths that were formed in PEEK rings that had a 0.5 cm i.d. and a 1 mm
depth. These monoliths were then placed onto on a glass slide. The slide was mounted on

the microscope stage with double sided tape, and the signal intensity for each dye solution
was measured with the NIR fluorescence microscope by scanning along the x-axis and
moving the stage in front of the microscope objective. It was found that the signal barely
increased from the background level when looking at the 10 nM dye solution and reached
almost the maximum level attainable by the microscope for 100 nM solution. The 500 nM
and 1000 nM solutions gave the maximum possible response, indicating saturation of the
microscope amplifier. Based on these results, the range of dye concentrations that were
used in the following experiments was selected to be between 10 to 100 nM.
A plastic sheet of silica gel, as is used in thin layer chromatography, was cut in 0.5
cm wide strips and glued to a glass slide. The slide was mounted on the microscope stage,
and the distance between this slide and the microscope objective was adjusted to provide
the maximum fluorescence signal. Two drops of IR CW800 dye standards were applied
over the top of each strip before scanning the strip along the x-axis. The results, as
presented in Figure 5.4, show an increasing intensity when going from the left to the right
(i.e., from 10 nM to 100 nM dye). The result obtained when no dye solution was present is
shown in red and included for comparison. These results show an observable range
between 10 and 100 nM of the IRDye 800CW dye on such a surface, with a limit of
detection of around 10 nM. It was also observed that the signal decreased when the scan
was repeated for the same strip if no fresh NIR fluorescent dye solution was added. This
signal reduction was believed to be due to quenching by oxygen or photobleaching of the
fluorophore [10,34].
The response of this system was compared with that of a benchtop
spectrofluorometer when the same dye solutions were measured on a Cary Eclipse

fluorometer that was equipped with a 96-well plate reader. No signal was detected on the
benchtop system at dye concentrations ranging from 10 nM to 100 nM, although a signal
was clearly seen for the 1000 nM stock solution.
A citrate-stabilized solution of AgNPs (18 nM) was mixed with the 10 nM and 20
nM dye standards in proportions ranging from 10 to 50% to see if the addition of these
nanoparticles gave any change in the dye’s fluorescent signal. However, no significant
increase in the signal was observed under these conditions.

Figure 5.4 (Top) Diagram showing the scan direction along the x-axis that was used for
silica strips that were mounted on a glass slide. (Bottom) Scan of silica strips
at 1000 revolutions/min (0.38 mm/s; the motor velocity, in revolutions per
min, was converted to mm/s by using the fact that 1 revolution is 64 counts
and 1 mm is 2800 counts) with the IRDye 800CW dye being present at the
following concentrations (from left-to-right): 10 nM, 20 nM, 40 nM, 60 nM,
80 nM and 100 nM. The last position on the right is for a blank that contained
no dye. The red tracing shows the results that were obtained for the same strip
when no dye was present throughout the strip.
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5.4.2. Fluorescence measurements of IR 800CW in microchannels and monoliths
The detection of the IR 800CW dyes in microchannels was studied by using a
microfluidic device that was made of PDMS, as prepared in collaboration with Dr. Stephen
Gross (Creighton University, Omaha, NE). This type of device had a straight microchannel
with a length of 2.2 cm and a cross section of 250 µm × 50 µm. The microchannel was
molded in a PDMS slab that was fixed to a glass slide. Teflon tubing was introduced
through holes made in the PDMS at 90° versus the glass slide and in contact with the ends
of the microchannel. An aluminum mounting plate with holes for directing the tubing was
attached with screws to the microscope stage. The microfluidic chip was fixed with tape
to the mounting plate, with the glass slide facing towards the microscope. The inlet tube
was directed through a hole in the mounting plate and connected with PEEK tubing and
adaptors to a syringe. The outlet was connected to a vial through another hole in the
mounting plate. The location of the microfluidic chip in this system is illustrated in Figure
5.5.
The distance of the microscope from the surface of the chip was initially set at 1.3
cm. A 100 nM solution of IRDye 800CW dye was applied to the microfluidic chip at 20
µL/min. The signal from the microscope was monitored while the chip was scanned in the
x-y plane to locate the microchannel. A camera with led illumination was used to assist in
locating the microchannel. In this way, the position of the laser dot could be seen on the
computer screen, avoiding the need to look directly into the enclosure that contained the
microscope and the stage.

Figure 5.5

Schematic showing the position of the microfluidic chip relative to the
microscope objective and the laser source. (Left) Lateral view showing the
location of the laser source behind the microscope objective. (Right) Front
view of the microfluidics chip, showing the position of the laser source and
the reflection of the laser dot when it was crossing the microchannel. The
microscope objective was centered in front of the microchannel (see dotted
circle). The scans were made on the x-axis and crossed the microchannel.
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Once a position for the laser beam had been located in the middle of the chip and
next to the microchannel, scans were made along the x-axis, as is shown in Figure 5.4.
These scans were made with the objective located at various different distances from the
microscope (i.e., by varying the distance along the z-axis) until a peak was observed when
the laser crossed the monolith containing the dye solution. The peak height became larger
as this distance was optimized until a maximum in the response was attained. This is
illustrated in Figure 5.6, which shows the variation in the signal intensity that was seen
when scanning was carried out at three slightly different distances between the objective
and the surface along the z-axis. In these results, the distance from the objective lens was
smaller than the distance obtained in the previous section due to the presence of the glass
slide that the laser has to cross before reaching the flowing dye solution. The apparent
reflection point of the laser on the aluminum mounting plate appeared to be shifted to the
left of the microchannel during detection because the laser source was located to the right
of the microscope lens at an angle of 45 ° versus the glass surface, as can be seen in Figure
5.5.
Different positions along the length of the microchannel were scanned, giving
similar results at the same scan velocities. These results indicated that the method of
measuring the fluorescence of the IRDye 800CW dye while it was flowing through a
microchannel with a 250 × 50 µm cross section and molded into a PDMA microfluidic
chip was reproducible and independent of the position along the channel’s length. Small
irregularities in the microchannel that may have been present did not appear to affect this
result.

Figure 5.6

Signals obtained at scans of 1000 revolutions/min (or 0.38 mm/s) that were
made at three distances, separated by 200 counts (or 0.071 mm), along the zplane from the microscope objective to the microfluidic chip surface.
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The effect of the scan velocity was studied by repeating the same type of scan at
0.038 mm/s (i.e., 1/10 the velocity used in the previous scans). The width of the peak for
the signal as well as the height of this peak increased, with the peak height going from
about 0.02 V to 0.06 V. The same level in the signal was reached when the laser was fixed
at one point over the microchannel and the flow was stopped; but there was also an
exponential decrease in the signal over time when dye was no longer flowing through the
microchannel. These experiments showed that the signal increased when the scan velocity
decreased and approached a maximum initial signal when the dye solution was not flowing.
However, this last situation also lead to a decrease in the signal over time, which probably
occurred due to photobleaching of the fluorophore [10,54].
The following experiments where performed for measuring the fluorescence of the
IR 800CW dye when it was flowing through the system. The microfluidic device was fixed
to the mounting stage with clamps or tape. The position of the device was adjusted while
a solution of 100 nM or 500 nM of the dye was passed at 20 µL/min through the
microchannel. The signal was scanned at a distance of 1.3 cm or less between the
microscope objective and the microchannel to find the position of the microchannel that
gave a maximum response. Another distance adjustment was then made by moving the
stage along the z-axis in increments going from 1000 counts and down 200 counts until a
final maximum signal was reached.
A manual injection of 0.5 µL of the dye solution was used for these experiments.
Solutions of the dye with concentrations of 500 nM, 50 nM, 20 nM or 10 nM were injected.
Figure 5.7 shows the results that were obtained for a 500 nM solution of the dye that was

injected at 5 or 20 µL/min. At least three injections were made at each concentration of
the dye and at each of these two flow rates.
As can be seen in Figure 5.7, decreasing the flow rate resulted in a larger peak in a
manner similar to what occurred from decreasing the scan rate. The same trend was
observed with the other concentrations of the dye that were studied. For the 10 nM dye
solution, the signal was only slightly distinguishable from the background noise at the
lowest flow rate that was tested (see Figure 5.8). By decreasing the flow rate, the time
needed for the dye to enter and pass through the microchannel was also increased. This
time could be decreased further by lowering the void time of the system (e.g., by decreasing
the length and internal diameter of the connecting tubing), which would help provide less
band broadening when this type of device is used in chromatographic separations or
experiments.
The 10 nM and 20 nM solutions of the dye were mixed with the AgNP stock
solution at various ratios to study the effect of these nanoparticles on the fluorescence
intensity of the NIR fluorescent dye. No fluorescence enhancement was observed under
these conditions.
The fluorescence of the dye was also measured in a 2 cm × 250 µm × 500 µm
microchannel that contained a GMA/EDMA monolith, which was prepared as described
in Sections 5.2.4 and 5.2.5.

Injections of a 0.5 µL portion of solutions with dye

concentrations ranging from 20 nM to 500 nM were made at 20 µL/min. The peaks that
were obtained showed some tailing, indicating that the dye may have been interacting with
the monolith, as can be seen in Figure 5.9. The calibration curve for these results gave a
linear response with a correlation coefficient of 0.9992 (r 2, 0.9984).

Figure 5.7

Injections of a 500 nM solution of the IR CW 800 carboxylate dye in pH 7.4,
0.067 M potassium phosphate buffer at several flow rates and onto a
microchannel with following dimensions: 2.5 cm × 250 µm × 50 µm.
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Figure 5.8

Injections of the IR CW 800 carboxylate dye at several concentrations in pH
7.4, 0.067 M potassium phosphate buffer. Conditions: injection volume, 0.5
µL; microchannel dimension, 2.2 cm × 250 × 50 µm; flow rate, (left) 20
µL/min and (right) 5 µL/min.
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Figure 5.9

(Top) Injections of 0.5 µL for several concentrations of the IR CW 800
carboxylate dye onto a 2 cm × 500 µm × 250 µm microchannel that was filled
a GMA/EDMA monolith and in the presence of pH 7.4, 0.067 potassium
phosphate buffer at 20 µL/min. (Bottom) Calibration plot obtained for these
same results.
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5.4.3. Fluorescence enhancement in EDMA/GMA monoliths
5.4.3.1. Adjustment of the fluorescence microscope controller
To achieve an appropriate dynamic range for measuring the signal from the NIR
fluorescence microscope, the optimum settings for the gain and offset in the microscope
controller where varied when using the 800 nm detection channel of this system. The
settings were optimized while the signal was used to monitor a 20 nM solution of the IRDye
800CW dye in pH 7.4, 0.067 M potassium phosphate buffer, which was applied at 25
µL/min through an empty glass capillary that was mounted on the stage and over a card
with a non-reflective black surface. The gain and the offset settings were adjusted so that
the output was about -0.034 V for the dye solution and -0.043 V for the background signal
that was present when looking at the black card. A similar background signal was obtained
when using a capillary that contained a flowing blank solution of pH 7.4, 0.067 M
phosphate buffer. This approach made it possible to ensure that the signal that was being
optimized was due to the fluorescence of the IRDye 800CW and was not due to reflected
or scattered light.
The voltages that were listed in the previous paragraph were located at the lower
end of the total possible voltage range (-0.06 to 0.06 V) of the detection system, which
allowed enough room for signals due to higher dye concentrations without being too close
to the minimum voltage. The gain of the controller was increased for detecting dye
concentrations at lower levels or decreased for the analysis of higher dye concentrations
while still keeping the voltage signal within the measurable range.

5.4.3.2. Preparation of monoliths with AgNP
Several attempts were carried out to incorporate AgNPs into GMA/EDMA
mixtures before they were polymerized for form monoliths by photoinitiation. Because the
aqueous solution of the citrate-stabilized AgNPs was immiscible with the other
polymerization components, aliquots of the AgNP solution were first dried at 60 °C;
however, it was not possible to later resuspend the AgNPs in either the polymerization
mixture or in one of the porogens (i.e., cyclohexanol).
In a second approach, a 18 nM solution of the AgNPs was placed into a Vivaspin
ultrafiltration column with a 300 kDa MW cutoff and a 6 mL capacity. The filtrating
element in this column was a double polyethersulfone membrane, which should have been
capable of retaining the AgNPs because their average diameter (i.e., 20 nm) was much
larger than the sizes of molecules that are able to pass through this type of filtration
membrane.
The spin time that was used for ultrafitration was found to be critical. The use of a
time that was too long resulted in all the AgNPs sticking to the membrane; it was not
possible to the resuspend these particles. The use of too little time for ultrafiltration
resulted in some of the original aqueous solution remaining in the tube, which caused
problems when attempts were made to later place the AgNPs into an organic solvent (i.e.,
giving two phases and poor dispersion). After several trials, it was found that the best
approach was to spin the AgNP solution for 30 to 60 s, followed by the careful addition of
a non-aqueous solvent (e.g., cyclohexanol) over the AgNP solution (i.e., without disturbing
the solution) and followed by centrifugation. The second centrifugation step of 1 min,
expelled the remaining water and allowed to obtain a pellet of AgNPs on the bottom of the

tube. Too much time yielded the AgNPs stuck to the membrane. Finally, the tube was
inverted twice to remove the AgNP pellet and the contents were poured into another tube.
After this new suspension had been mixed by vortexing at a high speed for 20 s, the
resulting suspension of AgNPs in cyclohexanol appeared to be homogeneous and, when
mixed with the rest of the components, gave a polymerization mixture that was stable for
several days.
Three preparations were made by using 1 mL, 3 mL or 5 mL of the original AgNP
solution and 1 mL of cyclohexanol. The final conditions that were used are listed in Table
5.2. Although it was not possible to recover all the AgNPs from the ultrafiltration tubes,
this method was fast and did produce a suspension of AgNPs in cyclohexanol that would
settle down very slowly and could easily be resuspended by vortex mixing.
Pictures of the AgNP suspensions in cyclohexanol are provided in Figure 5.10 as
well as UV/Vis spectra for the AgNPs in a 1:10 aqueous solution and for the
AgNP/cyclohexanol suspension. The aqueous solution spectrum shows a characteristic
maximum for AgNPs near 460 nm [5,24]. The spectrum of the AgNP/cyclohexanol
suspension was dominated by the background after 300 nm but had a small peak at 336
nm.

Table 5.2. Final conditions for dispersing AgNP in cyclohexanol (CyOH)

Condition

Volume of AgNP solution
1 mL
3mL

5 mL

Spin time before adding CyOH
(min)

0.5

1.5

2.5

0.5

0.75

1.0

2.0

2.0

2.0

Spin time after adding CyOH
(min)
Conditions used for spinning (g
× 10-3)1
1

The centrifugation temperature was 25 °C.

Figure 5.10 (Top) Suspensions of AgNPs in cyclohexanol (CyOH) that were made by
combining various volumes of a citrate-stabilized 18 nM AgNP solution
with 1 mL of cyclohexanol. (Bottom left) UV/Vis spectrum for a citrate
stabilized 2 nM AgNP solution in water. (Bottom right) UV/Vis spectrum
for a AgNP/cyclohexanol suspension made under the conditions shown in
Table 5.2 for a 3 mL of AgNP solution.

Monoliths based on the conditions that are listed in Table 5.1 were prepared with
cyclohexanol that contained AgNPs. The AgNP/cyclohexanol suspension was made
according to the conditions that are given in Table 5.2 when starting with 3 or 5 mL of
AgNP aqueous solutions. Another monolith preparation was made as a control that used
cyclohexanol but had no AgNPs present. Sections of glass slides were covered with layers
of adhesive tape for creating two pockets where the monolith mixtures containing AgNPs
or no AgNPs could be cast and polymerized through photoinitiation, as described
previously. After this process was completed, the slide now had a monolith layer that was
0.7 cm wide and about 1 mm thick, as shown in Figure 5.11.
Two types of monoliths were made on each glass slide: one containing a monolith
layer with AgNPs and the other without AgNPs. The system that was used to conduct NIR
fluorescent experiments with these slides was the same as depicted earlier in Figure 5.5.
Each glass slide was fixed to the mounting stage of the system with double sided tape. A
piece of adsorbent paper was attached to the mounting plate for collecting excess solution.
The initial position for the microscope objective was set at 1.3 cm from the surface of the
monoliths.

Figure 5.11 Glass slide with monolith layers containing or lacking AgNPs. A solution of
the NIR fluorescent dye was applied to the top of each monolith with a
dropper and allowed to flow downward across the monolith.
conditions are given in the text.

Other

A solution of the NIR fluorescent dye was applied with a dropper (e.g., four drops
of 100 nM dye) to the top of each monolith and allowed to flow across the monolith through
gravity. The fluorescence signal was recorded and the final distance between the monolith
and the microscope objective was adjusted by using small movements along the z-axis, as
described earlier. The signal was then recorded again while the dye solution was added to
the monolith. After making these measurements for one of the monoliths (e.g., the one
containing AgNPs), the microscope stage was moved to the other monolith and the process
was repeated. The signal intensity was then compared for the monoliths with or without
the AgNPs.
The results of the monolith made with 3 mL of the AgNP solution can be seen in
Figure 5.12. After the dye solution was added to the top of each monolith and the laser
was fixed at one spot on the monolith’s surface, there was an initial increase in the signal,
followed by a decrease as the dye solution moved across the monolith. The signal was
allowed to return to the background level before adding more solution and doing the next
measurement. Four measurements of this type were made at different spots on each
monolith. For a 100 nM solution of the dye, an initial increase in signal to about 0.01 V
was obtained on both types of monoliths. However, in the monolith with the AgNPs the
fluorescence signal increased further after the addition of the dye and was followed by a
much more gradual decrease. The overall result was that the signal after the addition of
the dye was about two-fold larger for this monolith than for the control monolith that
contained no AgNPs. When the concentration of the dye was decreased to 50 nM, an even
greater change in the initial signal and an overall increase in signal was seen for the
monolith with AgNPs versus the control monolith, as can be seen in Figure 5.12.

Figure 5.12 Fluorescence signals for solutions of the IR800CW dye that were applied to
monolith layers containing AgNPs or no AgNPs. The dye concentrations
were 100 nM (Top) or 50 nM (Bottom). The volume of the 18 nM AgNP
stock solution that was used to make the first monolith was 3 mL.
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The effect of increasing the AgNP concentration in the monolith was studied with
a glass slide that contained a monolith layer made using the conditions that are listed in
Table 5.2 for a 5 mL AgNP solution. The results were obtained at four different locations
of monoliths that contained AgNPs or no AgNPs. Some typical results are shown for a 50
nM dye solution in Figure 5.13. An initial increase of 0.010–0.014 V in the signal was
obtained when the dye solution was added to the top of the monolith with AgNPs. This
signal increased after addition of the dye and then decreased exponentially. On the other
hand, the monolith with no AgNPs showed an increase of only 0.001 to 0.0015 V when the
dye solution was added to the top of the monolith. In this case, there was a ten-to 18-fold
enhancement in signal on the monoliths that contained AgNPs. It should be noted that the
graphs of the second glass plate were obtained by using a lower gain setting in order to
bring the signal within the measurable range.
The fluorescence enhancement of the IRDye 800CW carboxylate dye was studied
with a 5 nM solution and by increasing the gain of the microscope controller. As is
demonstrated in Figure 5.13, the signal was easily seen in the monolith with AgNPs, but it
was not detectable in the monolith with no AgNPs. The gain of the system for these
experiments was close to the maximum that could be used with the instrument, but the
results show that it was possible under these conditions to detect dye concentrations well
below 1 nM on the GMA/EDMA monolith layer that contained AgNPs.

Figure 5.13 Fluorescent signal of IR800 CW dye solutions that were applied to monolith
layers containing AgNPs or no AgNPs. The monolith with the AgNPs was
made according to the conditions shown in Table 5.2 when using 5 mL of the
original AgNP solution. The dye concentrations were 50 nM (top) or 5 nM
(bottom). A signal due to the 5 nM dye solution was not detectable on the
monoliths that did not contain AgNPs.
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5.4.4. Fluorescence enhancement by AgNPs for monoliths in microfluidic chips
The fluorescence enhancement in EDMA/GMA monoliths containing AgNPs was
next examined by using these monoliths in microfluidic devices. PDMS microfluidic
devices were designed and produced for this work, as described in Section 5.2.4. These
microfluidic devices were placed onto the microscope mounting stage, according to the
procedures given in Section 5.4.2. Polymerization mixtures for the monoliths were made
according to the conditions in Table 5.2 that used 5 mL of the original AgNP solution. A
control monolith was made under the same conditions but without AgNPs. These mixtures
were injected into the microchannel of each microchip by using a syringe, and
polymerization was conducted as described previously.
When the dye solutions were first applied to these microfluidic channels, leaking
occurred at cracks that were next to the inlet holes or over the body of the PDMS chip.
These problems were caused by the backpressure that was generated by the monolith in the
microchannel, and were exaggerated by the fact that the flow stream approached the
monolith at a 90 ° angle. In an attempt to minimize or eliminate this issue, the cross section
of the microchannel was increased to 250 × 500 µm and the inlet tube was placed at an
angle of approximately 45° to the channel. These modifications reduced the problems with
leaking but did not eliminate them completely.
As a result, a new design for the microfluidic chips, as inspired by the experiments
with the monolith layers in the previous section, was next devised. These microchips were
made in collaboration with Dr. Stephen Morin’s lab and contained two micro-chambers
with dimensions of 2 mm length × 1 mm width × 100 µm depth. These two chambers were
connected to PE-60 tubing at the inlets. Monolith polymerization mixtures containing

AgNPs (made according to the conditions in Table 5.2 for a 5 mL AgNP solution) or
without AgNPs were injected into these chambers with a syringe and through the inlet
tubing. Photoinitiated polymerization was then carried out, and the inlets were connected
to a syringe pump, as described previously. The design of this device, as shown in Figure
5.14, allowed for lower back pressures to be obtained because the flow path was straight
from the inlet to the outlet and the monolith had a larger cross section. After their
preparation, the monolith chambers were washed for 15 min with pH 7.4, 0.067 M
potassium phosphate buffer at 50 µL/min. The optimum distance for detecting a flowing
100 nM IR 800CW dye solution was then determined by moving the stage versus the
microscope objective along the z-axis. Next, 0.5 µL injections were made for solutions
containing 0.5 to 100 nM of the IR 800CW NIR dye at 50 µL/min. This design allowed
for a rapid adjustment of the relative position of detection for comparing the response
between the monoliths with and without AgNPs.

Figure 5.14 PDMS microfluidic chip containing monoliths with or without AgNPs and
for use in the detection of IRDye 800CW in a flowing stream. (Top) Side
view showing the entrance of the polyethylene tubes next to the glass slide,
and the thickness of the PDMS plate. (Bottom) Front view showing the
monolith filled with AgNPs and the control monolith with no AgNPs present.
The size of monoliths were 2 mm long × 1 mm wide × 100 µm thick.
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Figure 5.15 Comparison of the response versus time that was obtained by injecting IRDye
800CW solutions at various concentrations into the monoliths that were made
with AgNPs or without AgNPs. Conditions: dye concentrations, (top) 60 nM
or (bottom) 80 nM; injection volume, 0.5 µL; flow rate, 0.5 µL/min.
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These results showed an effective fluorescence enhancement for the detection of
the NIR fluorescent dye by using the AgNPs. This enhancement was most noticeable when
comparing the peak areas that were obtained (see Figure 5.15). The observed trends were
similar to those obtained for monolith layers (see Section 5.4.3). The fluuorescence
enhancement made it easier to detect the dye at low concentrations. For instance, the
minimum concentration that could be detected for the NIR fluorescent dye in the presence
of the AgNPs was 1 nM, whereas it was 5 nM without the use of AgNPs.
To estimate the amount of fluorescence enhancement that was obtained, the average
peak areas for three injections were determined for each monolith and at each dye
concentration. The peak area ratios that were measured both with and without the use of
AgNPs were next determined at each dye concentration. The resulting enhancements in
the fluorescence were between 1.5- and 2.5-fold. Calibration plots of area vs. concentration
were also obtained for both types of monoliths. The correlation factors for these plots were
high (r2 > 0.95). The ratio between the slopes of the best-fit lines for the monoliths with
and without AgNPs was 1.9, which again indicated a two-fold fluorescence enhancement
with the monolith that contained AgNPs.

5.5.

CONCLUSIONS
Detection of a model dye was achieved by using a NIR fluorescence microscope

that was equipped with a laser light source and an x-y-z movable platform. This system
was used for scanning and detecting fluorescence of the dye IR 800CW in microchannels,
capillaries, monoliths, and monolith layers. This platform could be used in the future for
biointeraction systems based on microfluidic chips or affinity microcolumns that contain
monoliths based on GMA/EDMA, as has been previously demonstrated for the
immobilization of proteins such as HSA and AGP [32,33,55].

With the scanning

capabilities of this system, it was found that on-line detection could be carried out at several
points along a microchannel, which makes this method useful for on-column or postcolumn detection.
The addition of AgNPs to the GMA/EDMA monoliths, by mixing the AgNPs with
the porogen before polymerization, allowed for fluorescence enhancement of the IRDye
800CW. The results obtained in monolith layers that contained AgNPs showed at least a
ten-fold enhancement in signal at the highest concentration of AgNPs that was tested. The
signal was also more stable with the monoliths that had AgNPs than without AgNPs. The
minimum concentration of the fluorophore that could be detected was improved from 10
nM without AgNPs to less than 1 nM with the highest concentration of AgNPs used. Even
lower detection limits may be achieved by further increasing the AgNP content in the
monoliths and by further optimizing the detection parameters for the microscope system.
The fluorescence enhancement in a flow-based system was studied by injecting a
plug of NIR fluorescent dye into a microfluidic chip that contained microlayers of

GMA/EDMA. The results showed the same trend as with the dye solutions that were
applied directly to the monolith layers. The AgNPs had the effect of increasing the
fluorescence and producing a more stable signal. As a result of having a more stable signal,
a better correlation between peak areas and the dye’s concentration was also achieved. The
detection limit was reduced from 5 nM to 1 nM in the presence of the AgNPs, with about
a two-fold fluorescence enhancement being achieved when using monolith that contained
AgNPs.
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CHAPTER 6.
SUMMARY AND FUTURE WORK

6.1.

SUMMARY
The entrapment method for immobilizing biologically-related compounds in

chromatographic supports has been shown to be useful for preparing affinity ligands where
the ligand retains essentially full activity. The work in this dissertation included the
development of new approaches for increasing the amount of proteins that can be placed
in supports prepared by entrapment for high performance affinity chromatography (HPAC)
and the application of the newly developed supports for studying the interactions between
drugs and proteins.

As shown in this dissertation, HPAC with supports made by

entrapment can be used to investigate how the binding of proteins to drugs and small
solutes is affected by glycation. The use of microfluidics in HPAC and with monolithic
supports and using metal-based fluorescence enhancement for detection was also
considered.
The first chapter provided a general introduction to HPAC and the methods of zonal
elution and frontal analysis. Background information on the entrapment method was also
provided, along with a description of the potential advantages of this method over covalent
immobilization methods.
Chapter 2 examined ways of increasing the protein coverage, and therefore the
overall activity, of supports made by entrapment. This work included modifying the
conditions of the entrapment process in a slurry-based format. Human serum albumin

(HSA) was used as a model protein for these studies. The protein content for several
batches of silica supports that were made by entrapment was measured and the retention of
HPLC columns that were made with these supports was measured for solutes that bind to
HSA. Alternative ways of measuring the protein content of such supports, such as
fluorescence of labelled HSA and thermogravimetric analysis, were investigated as well.
Chapter 3 dealt with the development of a flow-based format for the entrapment of
proteins. The optimum conditions for obtaining supports with high protein contents with
this on-column entrapment method were found. The supports that were made by this
method were used in the study of interactions between HSA or lectins and probe
compounds that are known to bind these proteins. By using probes with known binding
constants for these proteins, it was possible to estimate the protein content of these supports
in columns without the need for disassembling these columns or destroying the support.
Changes in the bloodstream can occur during metabolic diseases, such as diabetes,
and produce modifications in serum proteins. One important example is the glycation of
HSA that occurs in diabetes. This modification can influence the binding of this protein
with some drugs, such as many sulfonylurea drugs that are used to treat type II diabetes.
In Chapter 4, samples of normal HSA and HSA with glycation levels characteristic of
patients with pre-diabetes, controlled diabetes or advanced diabetes were placed into
supports made by entrapment and the on-column method. The high protein contents that
were achieved by the on-column method, and the fact that the activity of this protein was
maintained in these supports, allowed the use of this method in a simplified approach for
measuring drug-protein interactions at specific sites on normal HSA or glycated HSA. This

was achieved by using competing agents for the given sites and measuring the shifts in
retention that occurred for a given drug in the presence of this competing agent.
The development of a microfluidic device that was suitable for use in on-column
or post-column detection in HPAC was discussed in Chapter 5. A monolith based on
glycidyl methacrylate-ethylene dimethacrylate (GMA/EDMA) co-polymer was placed into
such a device for use as a chromatographic support and a near infrared scanning
fluorescence microscope was used as the detector. The conditions that were needed with
this system for measuring a NIR fluorescent dye were established when using monoliths
and when the monoliths were placed into microchannels. This chapter also examined the
fluorescence enhancement that was obtained for the NIR fluorescent dye when silver
nanoparticles (AgNPs) were added to GMA/EDMA monoliths. The limit of detection was
decreased for monoliths contained AgNPs when compared to monoliths without AgNPs.
Overall, these results indicated that fluorescence enhancement by AgNPs was feasible in
microfluidic devices containing EGA/EDMA monoliths. These devices are attractive for
future use in biointeraction systems that may contain proteins or antibodies that are
immobilized into monolithic supports.

6.2.

FUTURE WORK
The work in this dissertation involved the development of high capacity supports

containing entrapped proteins for use in HPAC. This work has shown that an on-column
method of entrapment can provide the highest protein contents in column affinities while
also having minimal reagent consumption. The creation of encapsulated protein columns
with high protein contents has opened up many possible options for further implementation

of the entrapment immobilization method. For example, it should be feasible to study
analytes with low affinities by using columns with high protein coverage or to reduce the
column size for studying the interactions of drugs or metabolites with proteins that are
either expensive or that are isolated from a small amount of a sample (e.g., a serum sample
from a human or animal). It should also be possible with these small columns to combine
several columns together in microfluidic devices and to use them with fluorescence
detection to analyze samples with sizes in the sub-microliter range and target analytes at
sub-nanomolar concentrations.
The next logical step, after the implementation of the on-column method of
entrapment in this dissertation, would be the automation of the entrapment process. This
could be done by using a system of pumps for applying the reagents through a hydrazideactivated silica column, and a system of valves that can switch between the various reagent
solutions. One further step in automation would be to make a complete on-line entrapment
system where the protein that is to be entrapped (e.g., HSA) could also be isolated from a
biological sample (e.g., human serum) by using an antibody column for the protein,
followed by elution of the captured protein directly into the hydrazide-activated silica
support, where entrapment is then performed. Such a system would minimize loss of the
protein during sample handling steps and would provide a convenient way of entrapping
proteins or other biologically-related agents that are obtained from in vivo samples.
The fact that the protein remains fully active when it is immobilized by entrapment
should also make it possible with this method to create fast screening methods that can be
used to obtain the binding affinities for solutes with the entrapped proteins. As shown in
Chapter 4, this might be accomplished by simply measuring retention time shifts when this

solute is injected in the presence or absence of the entrapped protein. The entrapment
method could also be extended to additional ligands besides those examined in this
dissertation. Examples include other serum proteins (e.g., variants of the protein α1-acid
glycoprotein) or other lectins (e.g., jacalin or Sambucus nigra agglutinin). These lectin
columns could be used in studies for glycoproteomics in which the binding of the entrapped
lectins might be used for the isolation of glycopeptides or glycans prior to the analysis of
these analytes by methods such as mass spectrometry.
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